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Summary 
Migraine is a common neurological disorder with a high social burden and unknown 
pathomechanism. The trigeminal systems plays a crucial part in the pathological processes of 
the disease, therefore the knowledge about the functioning and modulation options of this 
system is essential for developing new therapeutic options against this condition. 
One of the animal models used in migraine research is the electrical stimulation of the 
trigeminal ganglion (ESTG). In this model we examined the activation pattern of the brain 
stem nuclei, previously regarded as migraine generators in human studies.  
To find new targets modulating the trigeminal nociceptive pathway we examined the 
effects of Brilliant Blue G-250 (BBG) and probenecid (PROB) on the number of c-Fos 
immunoreactive cells and on the changes in calcitonin gene-related peptide and neuronal 
nitric oxide synthase immunoreactivity in the caudal trigeminal nucleus. BBG is a P2X7 
receptor antagonist, which receptors were previously shown to be involved in nociceptive 
processing. PROB is an inhibitor of numerous organic anion transporters and multidrug 
resistance-associated proteins, and was proposed to be antinociceptive. BBG was tested in the 
ESTG model in two stimulation paradigms, a mild and a robust one, and in the orofacial 
formalin test, while PROB was tested in the formalin test only. 
After ESTG the activation pattern of the brainstem nuclei was not similar to the 
pattern seen during migraine attacks in human functional studies, suggesting that the 
activation of the trigeminal system in the rat does not lead to the activation of the migraine 
generator nuclei.  
BBG was effective in decreasing the activation of the second order trigeminal 
neurones only in the robust stimulation paradigm of ESTG, which suggest that P2X7 
receptors more likely play a fine-tuning role in of the trigeminal system, and are not general 
modulators. 
PROB had a clear antinociceptive behavioural effect and was able to decrease 
trigeminal activation after formalin, suggesting that one or even more of its molecular targets 
play a crucial part in trigeminal nociceptive processing. 
Our results provide important information about the functioning of the trigeminal 
system, thus contribute to the understanding of pathological processes underlying headache 
and migraine. 
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Introduction 
I. Migraine 
General characteristics 
 
Migraine is defined as a neurological disease characterised by spontaneous recurrent 
attacks of headache, lasting for 4-72 hours without treatment with accompanying symptoms 
of nausea, vomiting, photo-and phonophobia (1). In most of the cases the headache is 
unilateral and throbbing in nature, with moderate or severe intensity, and often worsened by 
physical activity (1). Migraine belongs to the family of primary headache disorders, implying 
that no other cause can be associated with the development of the disease. Despite the 
enormous research effort the exact pathomechanism of the disorder is still unknown. 
As a common neurological condition, migraine affects 14.7% of the population in 
Europe (2), mainly young adult people between 18 and 55 years of age (3). Therefore, the 
economical burden caused by the disease is significant (4), and underlines the need for further 
research seeking the answers for open questions in its pathomechanism.  
The migraine attack can be divided into four, often overlapping phases: the prodrome 
or premonitory phase, the aura phase, the headache phase and the postdrome. Of the four 
phases the aura and the headache phases are the most well studied, less is known about the 
pro-and postdrome phase. The aura is present in one-third of patients (5), giving the base of 
the main classification of the two most prevalent migraine types: migraine with and without 
aura (MA and MO respectively) (1). 
Migraine is more prevalent in women compared to men; after puberty the migraine 
occurrence ratio is approximately 3:1 (5). This fact suggests the involvement of female 
gonadal hormones in its pathomechanism (6). 
Among others, family aggregation studies suggest, that migraine has a predominantly 
genetic background (7, 8), but the exact genes were identified only for the very rare 
monogenic forms (familial hemiplegic migraine type I, II, and III). In case of MA and MO 
studies suggest that multiple loci are affected with some overlapping genes in both forms, but 
might also support the possibility, that the two common forms of migraine have different 
genetic background (9-11). 
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Pathomechanism 
 
One of the challenges of migraine research is to consider all four phases as one entity, 
and finding a complex explanation to all of the occurring symptoms. Several theories emerged 
during the years to explain the pathomechanism of migraine, and the subsequent research 
induced by these theories resulted in important discoveries about the occurring processes. 
However no theory proved to be completely applicable to explain the cause and all the 
detailed aspects of the disease. 
The first concept was proposed in the 1950’s based the work of Ray and Wolff 
regarding the observations of the pain sensitive structures of the head (12). The main 
hypotheses of this theory were, that intracranial vasospasm is causing the aura symptoms, 
while extracranial vasodilatation is responsible for the migraine pain (13). The theory 
promoted intensive research in the field of vascular changes in migraine, and indirectly 
facilitated the development of the triptans, the migraine specific drugs approved by the FDA. 
However the vascular changes do not explain all of the symptoms of the attack. 
The neurogenic theory stated that the primary origin of migraine is neuronal (14). The 
vascular and neuronal theory was combined based on the work of Moskowitz and colleagues 
(15-17). In this view the primary cause of the headache derived from the activation of the 
primary afferent neuronal fibres, which released inflammatory substances, affecting vascular 
tone and leading to plasma protein extravasation, resulting in neurogenic inflammation. The 
initiating step, however is not completely known in these models. 
With the widespread availability and development of functional imaging methods the 
precise mapping of the migrainous brain became possible. Weiller and colleagues detected, 
that during spontaneous migraine attacks the dorsolateral pons and the dorsal midbrain 
involving the nuclei nucleus raphe magnus (NRM), nucleus raphe dorsalis (DR) locus 
coeruleus (LC) and the periaqueductal grey matter (PAG) are activated and their activation 
persist even after the successful pain control with sumatriptan (18). These observations 
support the neuronal origin of the disease and were confirmed by other research groups in 
case of spontaneous and also during nitroglycerin induced migraine attacks (19-21). This 
activation was shown to be migraine specific, as was not present after injection of capsaicin to 
the head (22). These observations provided the foundation of the theory that the above 
mentioned nuclei initiate the migraine attack, they are the “migraine generators”. Although, it 
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is not clear whether this activation is the cause of the attack, or just a secondary phenomenon 
related to pain sensation. 
These activated nuclei are part of the endogenous pain modulating system. The NRM 
is found in the ventral midline of the brainstem and gives rise to the main modulating pathway 
affecting directly the spinal cord dorsal horn, and the caudal trigeminal nucleus (TNC) (23). It 
contains serotonin and GABA positive cells, and the two neurotransmitters often co-localize 
there (24). Together with the paragigantocellular reticular nucleus and the gigantocellular 
reticular nucleus pars alpha it forms the rostral ventromedial medulla (RVM). In the RVM 
ON, OFF and NEUTRAL cells can be found, identified by their firing pattern related to 
nociceptive stimuli (25). ON cells begin to fire just before the happening of a nociceptive 
withdrawal reflex; while OFF cells cease firing at the start of the same reflex. The firing 
pattern of NEUTRAL cells remains unchanged. Based on these observations ON cells are 
thought to be pro- while OFF cells are thought to be antinociceptive, but the mechanisms by 
which these cells are able to modulate nociceptive processing are under intensive research 
(26). 
The PAG sends a scarce input to the trigeminal complex directly (27), but it has dense 
projections to the NRM, and similarly the ON, OFF and NEUTRAL cells can be identified 
also in the PAG (28). Functionally the PAG is organized into columns, which have different 
neurotransmitter content and projection sites (29). A number of studies suggest that the 
sensation of pain and the reactions evoked by a painful stimulus are modified according to the 
environmental factors and to the behavioural state of the individual. The PAG is considered as 
one of the integrators of different sensory and behavioural information (30). Stimulation of 
the PAG was able to reduce the activity of trigeminal primary afferents in cats, confirming its 
involvement in trigeminal pain processing (31). 
Locus coeruleus is one of the main noradrenergic nuclei in the brain, sends dense 
projections to both higher order brain areas and to the spinal cord dorsal horn (32). 
Stimulation of the LC can produce analgesia (33), and may exert similar effector function in 
pain modulation as the RVM (34). It has dense projections to the TNC (35) and to the intra- 
and extracranial vasculature, suggesting a possible involvement in the vascular events of 
migraine (36). 
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The DR is embedded between the ventrolateral columns of the PAG, and is the largest 
serotonergic nucleus in the mammalian brain (37). Similarly to the previously mentioned 
nuclei, stimulation of the DR can also produce analgesia in experimental animals (38). The 
DR can exert its modulatory effect on the nociceptive processing directly in the trigeminal 
system (39, 40), or in a more feasible way throughout its dense projections to the NRM (41). 
All of the “migraine generator” nuclei are important elements of the pain modulating system, 
however their initiating role in the migraine attack remains elusive. 
An intensively investigated process in migraine pathomechanism is the cortical 
spreading depression (CSD). During this phenomenon a spreading depolarization wave moves 
across the cortex from the occipital to the frontal direction, followed by hyperpolarisation and 
blood flow changes. Based on the findings of Leao about the velocity of CSD waves (42) and 
the results of functional imaging studies it was suggested that CSD is the pathophysiological 
substrate of migrainous aura (43, 44). Whether the CSD is capable of initiating a migraine 
attack or not, is in the focus of current migraine research, but data gathered so far are 
controversial.  
From the data detailed above we can conclude that the pathophysiology of migraine is 
still an interesting and highly controversial research area. To understand the mechanism of 
headache generation during the attack, the knowledge about the functioning of the trigeminal 
system, which conveys sensory information from the head, is essential.  
 
II. Animal models of trigeminal activation 
 
Based on experimental data the most debilitating aspect of the migraine attack, the 
headache is due to the activation of the primary afferents of the trigeminal system (45). The 
primary afferents of the fifth/trigeminal nerve innervate the oral, facial and cranial territories 
of the head and convey nociceptive information to the central nervous system. The trigeminal 
nerve is divided into three branches, the ophthalmic (V1), the maxillary (V2) and to the 
mandibular (V3) branch. Nociceptive information from the branches is transmitted throughout 
the sensory ganglion of the trigeminal system, the trigeminal or Gasserian ganglion, which is 
situated at the anterior surface of the pars petrosa of the temporal bone. The central 
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projections of the primary nociceptive neurons terminate in the superficial layers of the upper 
cervical segments and in the TNC, forming the trigemino-cervical complex. 
The brain parenchyma itself is not reactive to painful stimuli, the vasculature and the 
meninges are the origin of nociceptive signals intracranially (12). The supratentorial dural and 
pial tissues are mainly innervated by the ophthalmic branch of the trigeminal nerve while the 
infratentorial parts are innervated by the upper cervical nerves (C2,C3) (46). 
To study the functioning of the trigeminal system and to reveal the mechanism 
involved in the generation of migrainous headache animal models are used. Unfortunately, no 
animal model has been developed so far which would be able to completely reflect all the 
genuine characteristic of a human migraine attack, however they are very useful in the testing 
of distinct features of headache mechanisms and the activation of the trigeminal system. 
One of the animal models of trigeminal activation is the electrical stimulation of the 
trigeminal ganglion (ESTG). In 1987 Markowitz and colleagues showed, that neurogenic 
plasma protein extravasation can be evoked by ESTG (15), and suggested that the release of 
neuropeptides is a key factor in this phenomenon. This was confirmed by detecting increased 
calcitonine gene-related peptide (CGRP) levels from the superior sagittal sinus in rats (47) 
and from the external jugular vein from cats and human patients after ESTG (48). 
Sumatriptan and ergot alkaloids, which are also used in migraine therapy, were able to inhibit 
plasma protein extravasation (49, 50) suggesting that neurogenic inflammatory mechanisms 
are participant is the process of migrainous headache generation. The activation of the second 
order neurones at the level of the TNC was also shown after ESTG with the aid of the 
detection of the messenger RNA of the immediate early gene c-fos (51) and also with the 
detection of the protein product c-Fos (52). C-Fos is activated shortly after different stimuli 
and is widely used to detect nociception related activity changes in the trigeminal system (53). 
In the ESTG model the amount of c-Fos immunoreactive cells in the TNC is highly dependent 
on the applied stimulation intensity and frequency (54) indicating that the utilization of 
various stimulation settings may be advisable.  
Subcutaneous (s.c.) injection of formalin is commonly used to examine inflammatory 
pain reactions in animals both at the behavioural and at the molecular level (55). A specific 
version of the formalin test is when the stimulus is applied to the whisker pad of the animals 
leading to the activation of the trigeminal system, the orofacial formalin test (56). The 
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behavioural reaction to the injected formalin is the immediate shaking of the head and 
scratching the injected area with the ipsilateral fore or hind paw. The behavioural response 
presents in two phases. The first phase is short-lasting and begins immediately after the 
application of formalin, and thought to be caused by the direct effect of formalin on 
nociceptors, mainly on C fibers (57). The second phase begins after a quiescent period, is 
more prolonged and presumably caused by inflammatory mechanisms (58). Besides the 
behavioural effects, a clear activation of the trigeminal system is also detectable in the 
orofacial formalin test. The c-Fos increase demonstrated activation presents according to the 
somatotopy at the level of the TNC (59). The test is used to identify possible new migraine 
therapeutic targets (60). 
III. Purinergic receptors and nociceptive processing 
 
The purine molecule ATP was proposed to have an important role in the regulation of 
nociceptive transmission (61). Purinergic receptors sensitive for ATP are divided into two 
main classes, the P2X and P2Y receptors and their agonist and antagonists have been proven 
to be effective in modulating different pain conditions, e.g. neuropathic and inflammatory 
pain (62). Among the ligand-gated P2X receptors the P2X7 receptor (P2X7-R) has been 
intensively studied in different pain states. The P2X7-R is a non-selective cation channel, 
unique among the P2X-Rs by virtue of its long C terminal domain, and its ability to open a 
pore permeable to molecules up to 900 Da (63). Experiments with knock-out mice have 
revealed that absence of the P2X7-R leads to the disappearance of mechanical and thermal 
hypersensitivity in models of neuropathic and inflammatory pain, whereas normal nociceptive 
processing is retained (64). P2X7-R antagonists have been examined in similar models, and 
the results underline the importance of the P2X7-R in chronic pain conditions (65, 66). 
Results from an acute inflammatory pain model suggest that the P2X7-R may participates in 
the development of central sensitization (67), a common feature in the trigeminal system 
during migraine attacks manifested by the presence of allodynia (68). 
However, little information is available as concerns the role of P2X7-Rs in the 
trigeminal system. In a model of orofacial pain, the chronic constriction injury model, 
inhibition of the P2X7-R led to a decrease in tactile allodynia through a p38 
mitogen-activated protein kinase-dependent mechanism (69). Gölöncsér and Sperlágh 
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recently reported that blockade of P2X7-Rs in mice by Brilliant Blue G-250 (BBG) reduced 
thermal hyperalgesia after systemic nitroglycerin administration (70). BBG is a selective, 
non-competitive P2X7-R antagonist, with good blood-brain barrier permeability (71) and was 
earlier proposed to be effective in neuropathic pain models (72). These results lend support to 
the theory that P2X7-Rs may play a crucial part in the development of headache disorders. 
IV. Probenecid and nociceptive processing 
 
Probenecid (PROB, p-(di-n-propylsulfamyl)benzoic acid) has primarily been used to 
enhance penicillin concentration in the serum by inhibiting the renal clearance throughout the 
inhibition of organic anion transporters (73) and to increase the renal excretion of uric acid to 
treat gout (74). Data also suggest that PROB may has anti-inflammatory and antinociceptive 
properties, related to several mediators participating in nociceptive and inflammatory 
conditions. One of this mediators is the multidrug resistance-associated protein 4 (MRP4), an 
organic anion transporter of which PROB is an inhibitor (75). MRP4 plays a crucial role in 
the release of prostaglandin E1 (PGE1) and prostaglandin E2 (PGE2) key inflammatory 
mediators (76), thus PROB could modulate prostaglandin related inflammatory processes. 
Furthermore, PROB is an agonist of the transient receptor potential channel subtype A 
member 1 (TRPA1) (77) and the transient receptor potential channel subtype V member 2 
(TRPV2) (78), both being involved in modulation of pain sensation (79, 80). The agonist-
mediated desensitization of these TRPA1 and TRPV2 channels can occur (77, 81), resulting 
in analgesia. In contrast, it was also proposed that probenecid can elicit the pain induced by 
inflammation through its agonism on TRPV2 (78). PROB also blocks the pannexin-1 channel 
(PANX1) (82), which is involved in neuronal inflammatory processes (83). Several studies 
suggest that PANX1 and the P2X7-R are in interaction during inflammatory processes (84, 
85), and their modulation could provide new therapeutic options in the treatment of chronic 
pain states (86). These results strongly suggest that PROB might has a mitigating effect on 
inflammatory and nociceptive mechanisms.  
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Aims 
 
Our aims in the present study were 
 
I. To evaluate the activation pattern of the migraine generator nuclei after electrical 
stimulation of the trigeminal ganglion at different survival times in the rat. 
 
II. To examine the effects of a purinergic P2X7 receptor antagonist, BBG on the 
activation in the TNC caused by two different electrical stimulation settings. 
 
III. To test the effects of BBG in the orofacial formalin test of the rat both at the 
behavioural and on the molecular level. 
 
IV. To detect the effects of probenecid on behaviour and on nociceptive activation in 
the orofacial formalin test of the rat. 
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Materials and methods 
I. Animals  
The procedures used in all experiments followed the guidelines of the eighth edition of 
the Guide for the Care and Use of Laboratory Animals and the Use of Animals in Research of 
the International Association for the Study of Pain and the directive of the European 
Economic Community (86/609/ECC). Experiments were approved by the Committee of 
Animal Research at the University of Szeged (I-74-14-16/2008; I-74-12/2012) and the 
Scientific Ethics Committee for Animal Research of the Protection of Animals Advisory 
Board (XI./15.1/02384/001/2007; XXIV/352/2012). Adult male Sprague-Dawley rats were 
used. They were raised and maintained under standard laboratory conditions on a 12h light-
dark cycle, with tap water and rat chow available ad libitum. Suffering of the animals and the 
number of animals used were kept at minimum. 
 
II. Activation pattern after trigeminal stimulation 
Experiments 
 
Twenty-six rats were divided into two groups. The animals in the first group (n=13) 
were deeply anaesthetized with chloral hydrate (400 mg/kg) and placed in a stereotaxic frame 
(Stoelting Co.). A hole was drilled with a dental drill 3.2-3.4 mm posterior to and 2.8-3.2 mm 
laterally from the bregma. A concentric bipolar electrode (FHC Inc., CBBRE75) was lowered 
to the right trigeminal ganglion, and maintained in it for 30 min. After surgery, the animals 
were kept under deep anaesthesia, additional doses of chloral hydrate if needed being given. 
They were returned back to their cages and were kept warm. 
The animals in the second group (n=13) underwent a similar surgical procedure, but 
were additionally stimulated for 30 min with square twin pulses at 10 Hz, 0.5 mA, with a 
pulse duration of 5 ms (Medicor, Electrostimulator ST3). The applied stimulation frequency 
induces depolarization, thus rapid firing of the pseudounipolar neurones of the trigeminal 
ganglion, and the intensity applied ensures that the area of the stimulation covers the entire 
trigeminal ganglion (87). 
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The correct placement of the electrode was checked by the twitching of the jaw when 
the electrode reached the ganglion, and was confirmed during the autopsy. The same was 
done in the subsequent stimulation paradigms too. 
From both groups 7 animals were perfused transcardially two hours after the 
placement of the electrode, while 6 animals were perfused four hours after the electrode 
placement, with 100 mL cold 0.1 M phosphate buffered saline (PBS), followed by 500 mL 
4% paraformaldehyde in 0.1 M phosphate buffer. The brains and cervical spinal cord were 
removed and postfixed overnight in the same fixative. 
 
Immunohistochemistry 
 
After cryoprotection 30 µm thick serial sections were cut 1 mm rostrally and 5 mm 
caudally from the obex, representing the TNC. The series were collected into 18 wells, the 
distance between consecutive sections was 540 µm.  
Similarly 30 µm thick serial sections were cut from the brainstem, the series started 
1.5 mm rostrally from the obex and 30 series were cut from each animal. The series were 
collected into 10 wells, the distance between consecutive sections therefore being 300 µm. 
The free-floating sections were rinsed in PBS and immersed in methanol containing 
0.3% H2O2 for 30 min. After several washes in PBS containing 1% Triton X-100 (PBS-T), the 
sections were blocked for 1 hour in PBS-T containing 10% normal goat serum (NGS). 
Sections from the TNC were incubated for one night at room temperature in PBS-T 
containing 2% NGS and 1:2000 anti c-Fos primary antibody (rabbit anti-human c-Fos 
polyclonal antibody, Santa Cruz Biotechnology, sc-52), while sections from the brainstem 
were incubated for 2 nights at 4°C in PBS-T containing 2% NGS and 1:1000 anti c-Fos 
primary antibody (same as previously). The immunohistochemical reaction was visualized by 
the avidin–biotin kit of Vectastain (Vector Laboratories Inc., PK-6101) and stained with 
nickel ammonium sulphate-intensified 3,3’-diaminobenzidine for sections of the TNC and 
3,3’-diaminobenzidine without intensification for sections of the brainstem. The specificity of 
the immune reaction was checked by omitting the primary antiserum. On brainstem sections 
toluidine blue counterstaining was applied to facilitate cell counting. 
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Cell counting 
 
The c-Fos-immunopositive cells were counted according to Paxinos and Watson (88) 
in the TNC, NRM, DR, ventrolateral periaqueductal grey (VLPAG), lateral periaqueductal 
gray (LPAG), dorsolateral periaqueductal gray (DLPAG), dorsomedial periaqueductal gray 
(DMPAG) and LC separately. Sections were examined under a Zeiss Axio Imager M2 
Upright Microscope (Carl Zeiss MicroImaging,) supplied with an AxioCam MRc camera 
(Carl Zeiss MicroImaging). Photographs were taken on 20X magnification, using the MosaiX 
program feature of the AxioVision software. Cells were counted and area of the different 
nuclei were delineated and measured on one series of sections from the TNC and from the 
brainstem in each animal. Cell counting was made by an investigator blinded to the 
stimulation procedure, furthermore stimulated and unstimulated sides of the sections were 
counted separately. 
 
Statistical analysis 
 
For the different nuclei, cell counts per side and per series were summed and divided 
by the corresponding area. In this way the cell count per µm2 was calculated for each side and 
for each series in each animal. 
In case of the TNC, counts were averaged by animal and statistical comparison was 
made using ANOVA (SPSS Statistics 17.0 for Windows, Games-Howell post hoc test). 
In case of other paired nuclei of the brainstem the first step was to determine if there is 
any difference between the sham and stimulated sides using Student’s t-test. There was no 
significant difference in any of the nuclei, therefore, data from separate sides were pooled. 
These data were than compared using ANOVA (SPSS Statistics 17.0 for Windows, Scheffe 
post hoc test). 
Statistical comparison in the NRM and DR was also conducted by ANOVA (SPSS 
Statistics 17.0 for Windows, Scheffe post hoc test). 
Linear regression analysis was conducted to examine if there is any correlation 
between the cell number changes in the TNC and NRM (SPSS Statistics 17.0 for Windows). 
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III. Effects of BBG after trigeminal activation 
Mild stimulation procedure 
 
Twenty-four animals (250-300 g) were used. Half of the animals received an 
intravenous (i.v.) injection of 50 mg/kg BBG, while the other half was injected with the 
vehicle of BBG, physiological saline. Two hours after the BBG or saline injection, the 
animals were deeply anesthetized with chloral hydrate (400 mg/kg) and the surgical procedure 
as stated in the previous section was performed. Half of the animals from the saline-treated 
group (5SStim) and half of the animals from the BBG group (5BStim) were electrically 
stimulated for 5 min with 5 Hz, 0.5 mA, 0.5 ms delay twin pulses. The other animals from 
both groups were used as sham animals: the electrode was lowered to the right trigeminal 
ganglion for 5 min, but no stimulation was performed (5SSham and 5BSham groups). After 
both procedures, the animals were returned to their home cages and maintained under deep 
anaesthesia covered by a warming blanket for 2 hours. 
 
Robust stimulation procedure 
 
Twenty-one animals (250-300 g) were used; the treatment and surgical procedures 
were identical to the previous ones, except that the stimulation parameters of 10 Hz, 0.5 mA, 
0.5 ms delay twin pulses were applied for 30 min, and the animals were maintained under 
deep anaesthesia, covered by a warming blanket, in their home cages for 4 hours from the 
beginning of the stimulation. These parameters are equivalent to the ones applied in the 
activation pattern experiments. 
Overview of the robust stimulation groups: 
Saline + 30-min sham: 30SSham (n=6) 
Saline + 30-min stimulation: 30SStim (n=5) 
BBG + 30-min sham: 30BSham (n=4) 
BBG + 30-min stimulation: 30BStim (n=6) 
 
Orofacial formalin test 
 
Rats (n=52, 200-240 g) were injected i.v. either with 50 mg/kg BBG or with 
physiological saline. One hour and fifty minutes later, the animals were placed in a 30x30x30 
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cm box, with mirrored walls for the monitoring of behavioural activity. After 10 min of 
habituation, the animals were taken out of the box and under minimal restraint were injected 
s.c. with 50 µL of either physiological saline (SSal and BSal groups) or with 1.5% formalin 
(SForm and BForm groups) to the right whisker pad. After the injection, they were returned 
immediately to the box and their behaviour was monitored for 45 min under video 
surveillance. The injection of formalin causes a behavioural response, which consists of 
rubbing and scratching the injected whisker pad with the ipsilateral fore- or hindpaw. The rate 
of this behaviour correlates with the pain sensation caused by formalin (56). The 45-min 
period was divided into 15x3-min blocks, and the total time spent rubbing the injected 
whisker pad, measured in seconds was taken as the nociceptive score in the given block. The 
normal grooming activity of the saline-treated animals was measured as control. After the 
monitoring period, the animals were returned into their home cages and maintained under 
standard laboratory conditions until perfusion, which was performed under deep chloral 
hydrate anaesthesia 4 hours after the whisker pad injections. 
 
Perfusion and immunohistochemistry 
 
The animals were perfused and sections from the TNC were prepared as previously 
described. The same staining method was applied as detailed earlier for c-Fos. For the CGRP 
staining the procedure was identical except for the primary antibody, which was used in a 
dilution of 1:20000 (rabbit anti-rat CGRP polyclonal antibody, Sigma-Aldrich C8198) 
overnight at room temperature. 
 
Cell counting and statistical analysis  
 
Cells immunopositive for c-Fos in the laminae I-II of the entire TNC were counted on 
a Nikon Optiphot-2 light microscope under a 20x objective.  
CGRP-stained sections were photographed with a Zeiss AxioCam MRc Rev.3 digital 
camera attached to a Zeiss AxioImager M2 microscope. Digital images were taken with a 
20X objective in TNC laminae I-II, and the area covered by CGRP-immunoreactive fibres 
was measured through the use of ImageProPlus 6.2 software (Media Cybernetics Inc.) by an 
observer blinded to the treatment procedures. 
 21 
The cell count results were aligned according to the rostro-caudal location of the 
section based on the anatomical observations compared to the atlas of Paxinos and Watson 
(88). Data from different levels of the TNC were handled separately, and analysed by two-
way repeated measures ANOVA. The group were used as the between-subject factor and the 
levels (-13.89, -14.43, -14.97, -15.51, -16.05, -16.59, -17.13, -17.67, -18.21 mm from bregma) 
as the within-subject factor for the analysis. 
When Mauchly’s test of sphericity proved to be significant, the Greenhouse-Geisser 
correction was performed. Pairwise comparisons of group means were performed on the basis 
of estimated marginal means with Sidak adjustment for multiple comparisons. 
The sums of the areas covered by CGRP-immunoreactive fibres were compared 
between groups according to the different levels, two-way repeated measures ANOVA being 
used as detailed above. 
Nociceptive scores from the behavioural study were compared block by block through 
two way repeated measures ANOVA. Groups were used as between-subject factor and blocks 
(1-15) as within-subject factor for the analysis. Other statistical parameters were identical to 
those mentioned above. 
For the comparison of the nociceptive scores in the two phases of the formalin test 
one-way ANOVA was used followed by the Tamhane post hoc test. The first block of three 
minutes was considered as the first phase, while the sum of the blocks 5-11 was the second 
phase. 
Statistical analyses were carried out with IBM SPSS Statistics, version 20 (IBM 
Corporation) software. All tests were two-sided, and p<0.05 was considered to be statistically 
significant.  
IV. Effects of probenecid after trigeminal activation 
Behavioural test and immunohistochemistry 
 
Sixty rats weighing 200-250 g were used, they were divided into two groups (n=30 per 
group). The animals in the Placebo group received only intraperitoneal (i.p.) vehicle solution 
(physiological saline, 1.5 mL) as pre-treatment. In the PROB group, the rats were pre-treated 
with an i.p. injection of PROB (Sigma-Aldrich; 1 mmol/kg body weight, diluted to 1.5 mL, 
pH 7.4). One hour after the PROB or vehicle pre-treatment, half of the animals in both groups 
received a s.c. injection of 50 µl 1.5% formalin solution into the right whisker pad (Placebo-
 22 
Form and PROB-Form), while the other half of the rats were injected with s.c. 50 µL 
physiological saline without formalin (Placebo-Phys and PROB-Phys).  
The behavioural experiments were conducted as described previously at the BBG 
experiments, the habituation period starting fifty minutes after the pre-treatments. 
Four hours after the formalin or saline injections animals (n=10) processed for 
immunohistochemistry were transcardially perfused as described above. After cryoprotection 
the TNC was sectioned into ten wells containing cold PBS, and fifteen series of sections were 
collected into each well. The free floating sections were processed for c-Fos immunostaining 
as previously described. For nNOS the applied staining procedure was identical except for the 
primary antibody, which was used for two nights at 4°C in a dilution of 1:5000 (rabbit anti-rat 
nNOS polyclonal antibody EuroProxima, B220-1). 
 
Western blotting 
 
Four hours after the formalin or physiological saline injection, the rats (n=5 per group) 
were deeply anaesthetized with chloral hydrate, perfused transcardially with 100 ml ice cold 
PBS and the ipsi- and contralateral side of the TNC between 0 and -4 mm from the obex was 
removed. The samples were stored at -80°C. The TNC segments were sonicated in ice cold 
lysis buffer containing 50 mM Tris-HCl, 150 mM NaCl, 0.1% igepal, 0.1% cholic acid, 2 
µg/mL leupeptin, 2 mM phenylmethylsulphonyl fluoride, 1 µg/ml pepstatin, 2 mM EDTA and 
0.1% sodium dodecyl sulphate (SDS) (all chemicals were from Sigma-Aldrich). The lysates 
were centrifuged at 12,000 RPM for 10 min at 4°C and supernatants were aliquoted and 
stored at -20°C. Protein concentration was measured with the BCA Protein Assay Kit 
(Novagen) using bovine serum albumin as a standard. Samples were cooled on ice during the 
whole procedure. Prior to loading, each sample was mixed with sample buffer, and denatured 
by boiling for 3 min. Equal amounts of protein samples (20 µg/lane) were separated by 
standard SDS polyacrylamide gel electrophoresis on 12% Tris–Glycine gel and 
electrotransferred onto Amersham Hybond-ECL nitrocellulose membrane (0.45 µm pore size, 
GE Healthcare). The Page Ruler Prestained Protein Ladder (Fermentas, 10-170 kDa) was 
used to determine approximate molecular weights. Following the transfer, membranes were 
blocked for one hour at room temperature in Tris-buffered saline containing Tween 20 
(TBST, MP Biomedicals) and 5% non fat dry milk powder and then incubated in TBST 
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containing 1% non fat dry milk and rabbit anti-rat interleukin-1beta (IL-1β; H-153) polyclonal 
antibody overnight at 4°C or in mouse anti-rat β-actin monoclonal antibody (Calbiochem, 
CP01, dilution: 1:100,000, incubation: overnight at 4°C). Next day after several rinses in 
TBST, membranes were incubated in TBST containing 1% non fat dry milk and horseradish 
peroxidase-conjugated anti-rabbit or anti-mouse secondary antibody (Santa Cruz 
Biotechnology; sc-2030 and sc-2031) for 2 hours at room temperature. Protein bands were 
visualized after incubation of membranes with the SuperSignal West Pico Chemiluminescent 
Substrate (Pierce) using Carestream Kodak BioMax Light film (Kodak).  
For densitometric analyses, films were scanned and quantified using Java ImageJ 
1.47v analysis software (National Institutes of Health). The β-actin was used as sample 
loading control and normalization protein as well.  
 
Statistical analysis 
 
Statistical analysis of the behavioural data was conducted as described at the BBG 
orofacial test. 
The numbers of IR neurones in the various groups were compared at the 15 levels 
along the rostrocaudal axis by using two-way repeated measures ANOVA described in details 
at the BBG experiments. Since there was no significant difference in the number of c-Fos- 
and nNOS-IR neurones between the contralateral sides in the groups injected with formalin 
and the contra- and ipsilateral sides in the groups injected with physiological saline (data not 
shown), in the course of the statistical analysis the data obtained from the contralateral sides 
of the groups injected with formalin were used as controls. The contra- and ipsilateral sides of 
the formalin-injected groups were used as the between-subject factor, and the 15 levels along 
the rostrocaudal axis as the within-subject factor for the analysis. 
Statistical analysis of the Western blot data was carried out using one-way ANOVA 
followed by the Sidak post hoc test. Since there was no significant difference in band 
densities between the contralateral sides in the groups injected with formalin and the contra- 
and ipsilateral sides in the groups injected with physiological saline (data not shown), in the 
course of the statistical analysis the data obtained from the contralateral sides of the 
subgroups injected with formalin were used as controls. 
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Results 
I. Activation pattern after trigeminal stimulation 
 
Activation of the TNC after trigeminal ganglion stimulation was previously 
demonstrated by several studies (54, 89). Our results also show the clear activation of the 
ipsilateral side of the TNC, while on the contralateral side, and in the sham animals no 
significant increase in c-Fos cell number could be detected (Fig 1). The different survival 
times did not show significant alterations in c-Fos positive cells, however at 4 hours a 
decreasing tendency in the cell numbers can be observed (Fig 2). 
Among the brainstem migraine generator nuclei we found significant increase in the 
number of c-Fos positive cells only in the NRM (Fig 3), the other nuclei (LC, DR, VL PAG, 
L PAG, DL PAG, DM PAG did not show alterations in c-Fos expression after stimulation 
(Fig 4). Furthermore, no side difference could be noticed in these nuclei, the cell numbers on 
the stimulated and on the control sides were similar. The different survival times did not 
influence the cell numbers in the different nuclei, with one exception, in the LC the c-Fos 
positivity decreased after 4 hours survival compared to the 2 hours survival group (Fig 4). The 
linear regression analysis did not reveal a significant connection between the increased cell 
number is the TNC and NRM (R2= 0.252; F=3.708; p=0.80).  
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Figure 1. 
Representative photos of the TNC from a sham (a, c) and from a stimulated animal (b, d) 
taken approximately 0.5 mm caudal from the obex after 2 hours survival. More cells can be 
detected on the electrode side of the stimulated animal (d) compared to the electrode side of 
the sham animal (c). Scale bars 500 µm (a, b) 100 µm (c, d). 
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Figure 2. 
Diagram showing the average number of c-Fos IR cells per µm2 in the TNC after 2 and 4 
hours of survival after stimulation or sham surgery (group means per side +SEM). In the sham 
animals no increase in c-Fos cell numbers can be detected either in the electrode or in the 
control sides. However in both the 2 and 4 hours survival group a marked increase is present 
compared to the corresponding electrode sides of the sham animals. No significant difference 
is present between the cell numbers of the two different survival times (* p< 0.05; ** p< 
0.01). 
 
Figure 3. 
Diagrams showing the average number of c-Fos IR cells per µm2 in brainstem nuclei (group 
means +SEM). The highest cell number per area ratio was present in the LC, which is not 
surprising, considering the small extent of this nucleus. Statistically significant alteration 
between the sham and stimulated group could only be detected in the NRM (*p<0.05), where 
the stimulation increased the number of positive cells. There is a significant difference 
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(*p<0.05) between the two stimulated groups in the LC, but no such difference could be 
observed in the other nuclei.  
 
Figure 4. 
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Representative photos from the NRM taken from sham (b, d) and stimulated (a, c, e) animals 
after 2 hours (a, b, c) or 4 hours (d, e) survival approximately 4 mm rostral from the obex. 
Filled arrowheads indicate c-Fos positive cells, while unfilled arrowheads indicate c-Fos 
negative cells, counterstained with toluidine blue. After 2 hours of survival, c-Fos 
immunoreactive cells are more numerous in the stimulated group (b, c). Four hours after the 
stimulation the activation of the nucleus raphe magnus is still present (e). Scale bars 1000 µm 
(a) and 200 µm (b, c, d, e). 
 
II. Effects of BBG after trigeminal activation 
 
Mild stimulation procedure 
 
As a significant interaction was found between the two investigated factors (levels and 
groups, p<0.01) for the number of c-Fos-immunoreactive cells in the mild stimulation 
paradigm, both effects could not be reported independently, whereas the group differences 
could be examined separately across different levels on the basis of the estimated marginal 
means for multiple comparisons. 
The comparisons of the cell numbers from the control (left) sides for each of the four 
treatment groups did not reveal any significant changes (data not shown), therefore only the 
data for the stimulated (right) sides of the groups are presented in Fig 5 a-d. ESTG caused a 
significant increase in the number of c-Fos-immunoreactive cells along the whole extent of 
the examined region of the TNC (Fig 5 a, b, e). BBG exhibited a significant effect compared 
with the saline treated stimulated animals only at the level of -13.89 mm from bregma (Fig 5 
b, c, e).  
A significant interaction was found between the groups and levels, when the area 
values from the CGRP measurements were examined. However, the comparisons of the 
groups and stimulated-control sides at different levels did not reveal any significant alteration 
(Fig 6).  
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Figure 5. 
Summary of the results from the mild stimulation paradigm regarding c-Fos immunostaining. 
Representative photos from the right sides of the four treatment groups after c-Fos 
immunohistochemistry, taken at 16.05 mm caudally from bregma: (a) 5SSham, (b) 5SStim, 
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(c) 5BSham, (d) 5BStim. Scale bar 200 µm. Diagram showing the number of c-Fos-
immunoreactive cells across the different levels of the TNC after mild electrical stimulation 
of the trigeminal ganglion (group means ± SEM) (e). There was no significant difference 
between the control (left) sides (data not shown). For clarity, only the control side of the 
saline-treated stimulated group is presented. The hashmarks indicate significance in the 
comparison of the right sides of the 5SSham and 5SStim groups at different levels of the TNC 
(#p<0.05; ##p<0.01; ###p<0.001). BBG treatment showed an attenuating tendency, though it 
proved to be significant merely at the level of 13.89 mm (**p<0.01, 5SStim – 5BStim). 
 
Figure 6. 
Diagram showing the area covered by CGRP-immunoreactive fibres at the different levels of 
the TNC in the different treatment groups after mild electrical stimulation of the trigeminal 
ganglion (group means ± SEM). There was no significant difference between either the 
control or the stimulated sides or the different groups. For clarity, only the control side of the 
saline-treated stimulated group is presented. 
 
Robust stimulation procedure 
 
A significant interaction was not found between the investigated factors of levels and 
groups for the number of c-Fos-immunoreactive cells in the robust stimulation paradigm. The 
levels had a significant effect (p<0.001), and there was also a significant difference between 
the groups (p<0.001). Pair wise comparisons revealed that there was no significant difference 
between the control sides of the four treatment groups (data not shown). Robust stimulation 
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caused a marked increase in the number of c-Fos IR cells in the saline-treated animals (Fig 7 
a, b, e, 30SStim compared with 30SSham). BBG had a significant attenuating effect on this 
increase (Fig 7 b, d, e, 30SStim compared with 30BStim).  
 
Figure 7. 
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Summary of the results from the robust stimulation paradigm regarding c-Fos 
immunostaining. Representative photos from the right sides of the four treatment groups after 
c-Fos immunohistochemistry, taken at 16.05 mm caudally from bregma: (a) 30SSham, (b) 
30SStim, (c) 30BSham, (d) 30BStim. Scale bar 200 µm. Diagram showing the number of c-
Fos-immunoreactive cells at different levels along the rostro-caudal axis in the TNC (group 
means ± SEM) in the robust stimulation paradigm (e). There was no significant difference 
between the control sides (data not shown). For clarity, only the control side of the saline-
treated stimulated group is presented. Electrical stimulation of the right trigeminal ganglion 
caused a significant increase in the number of c-Fos-positive cells as compared with the right 
side of the sham group at all levels examined (###p<0.001 30SSham – 30SStim). BBG 
treatment had a significant decreasing effect on the cell counts (*** p<0.001 30SStim–
30BStim). 
 
 
Figure 8. 
Diagram showing the area covered by CGRP-immunoreactive fibres at the different levels of 
the TNC in the different treatment groups after robust electrical stimulation of the trigeminal 
ganglion (group means ± SEM). There was no significant difference between either the 
control or the stimulated sides or the different groups. For clarity, only the control side of the 
saline-treated stimulated group is presented. 
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CGRP expression was not altered by stimulation or BBG administration in any of the 
animal groups in the robust stimulation setup (Fig 8). 
 
Orofacial formalin test 
 
A significant interaction was found between time and groups (p<0.05) during the 
analysis of the behavioural data from the orofacial formalin test. The pair wise comparison 
revealed that the nociceptive scores of the saline-injected groups (SSal and BSal) did not 
differ from each other at any time point (Fig 9). The injection of formalin caused a significant 
increase in the nociceptive scores in blocks 1 and 5-7 (Fig. 9, SForm compared with SSal). 
After the injection of formalin into the whisker pad, the BBG-treated animals demonstrated 
significantly increased nociceptive scores in blocks 1, 6 and 8 as compared with the control 
(Fig 9). The BBG-treated animals spent less time rubbing their formalin-injected side in both 
blocks 1 and 5-7, but this difference was not significant compared with the SForm group. In 
our experiments, the second phase of the formalin test subsided more quickly as expected in 
the SForm group, while it was more prolonged in the BForm group. 
 
Figure 9. 
Diagram showing the mean nociceptive scores (sec) in different time blocks from the four 
treatment groups (group means ± SEM, n=13) in the orofacial formalin test. The injection of 
formalin increased the nociceptive score in blocks 1 and 5-7 as compared with the saline 
injected animals (#p<0.05, ##p<0.01). BBG treatment did not affect the nociceptive scores 
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after saline injection, and did not modify the normal behaviour. The nociceptive scores of the 
BBG and saline-treated formalin-injected groups did not differ significantly in any block. 
 
 
Figure 10. 
Diagrams showing the nociceptive scores in the first (first block) and in the second (5-11 
blocks) phases of the formalin test. Formalin raised the rubbing activity in the saline treated 
group. BBG administration did not show any modulating effect on the nociceptive score 
raised by formalin (* p< 0.05; ** p< 0.01; ***p< 0.001). 
 
The two phases of the formalin test were distinguishable in our experiments, so we 
examined the data not just block-by-block, but also in the two phases separately. In the first 
phase of the formalin test an increase in the nociceptive scores can be seen in both the SForm 
and BForm groups. In the second phase a similar pattern could be observed, showing more 
clearly the lack of effect of the BBG treatment on formalin induced nociceptive behaviour. 
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Figure 11. 
Summary of the results from the orofacial formalin test regarding c-Fos immunostaining. 
Representative photos from the right (injected) sides of the four treatment groups after c-Fos 
immunohistochemistry taken at 16.05 mm caudally from bregma: (a) SSal, (b) SForm, (c) 
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BSal, (d) BForm. Scale bar 200 µm. Diagram showing the mean number of c-Fos 
immunoreactive cells along the rostro-caudal axis in the TNC in the orofacial formalin test 
(group means ± SEM) (e). Injection of saline did not cause any increase in the number of c-
Fos-positive cells (SSal and BSal groups). The effect of formalin was visible only on the 
injected side; the control sides were similar to those in the saline-injected controls. For clarity, 
only the control side of the SForm animals is presented. Formalin caused an increase in c-Fos 
cell number on the ipsilateral side as compared with the saline-injected side of the controls 
(SForm compared with SSal), significant at the levels -16.59 to -15.51 mm (###p<0.001). In 
the BBG-treated rats, formalin had a similar activity-increasing effect, significant at the levels 
-16.59 to -14.97 mm ($p<0.05; $$p<0.01; $$$p<0.001). The groups SForm and BForm did 
not differ significantly from each other. 
 
A significant interaction was observed between the levels and groups (p<0.001) for the 
number of c-Fos IR cells in the orofacial formalin test. There was no significant difference 
when either the control (left) sides or the control and saline-injected sides were compared at 
any level (Fig 11 e). The injection of formalin increased the number of c-Fos IR cells 
significantly at the levels -16.59 mm to -15.51 mm, mainly in the central part of the TNC as 
compared with the saline-injected side in the SSal group. In the BForm group, a similar 
pattern was observed, except that the difference involved one additional level (-14.97 mm, 
Fig 11 e). There was no significant difference between the SForm and BForm groups at any 
level (Fig 11 b, d). 
No group difference was found in any of the measured parameters regarding the 
CGRP immunoreactivity (Fig 12). 
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Figure 12. 
Summary of the results after CGRP immunostaining in the orofacial formalin test. 
Representative photos of CGRP immunohistochemistry on the right sides of the TNC from 
the four treatment groups taken at 14.97 mm caudally from bregma (a) 5SSham, (b) 5SStim, 
(c) 5BSham, (d) 5BStim. Scale bar 200 µm. Diagram showing the area covered by CGRP-
immunoreactive fibres at the different levels of the TNC in the different treatment groups in 
 38 
the orofacial formalin test (group means ± SEM) (e). There was no significant difference 
between either the control or injected sides or the different groups. For clarity, only the 
control side of the saline-treated formalin-injected group is presented. 
III. Effects of probenecid after trigeminal activation 
 
The behavioural pattern observed in our experiments was in accordance with previous 
findings, as animals showed increased grooming activity after the formalin injection. We 
found significant differences in the first and fifth to eleventh blocks (Fig 13) between the 
Placebo-Phys and Placebo-Form groups. The pre-treatment with PROB decreased the 
formalin-induced nociceptive behaviour significantly in each block (Fig 13). However, PROB 
pre-treatment did not abolish the effect of formalin completely in the first block, where the 
time spent on rubbing was still significantly higher than that in the Placebo-Phys group 
(Fig 13). There was no significant difference between the Placebo-Phys and PROB-Phys 
animals in any block, nor was between the PROB-Form and PROB-Phys subgroups in any 
other block apart from the first (Fig 13). 
 
Figure 13. 
Diagram showing the number of seconds spent rubbing the injected area with the ipsilateral 
fore- or hindpaw in each block. In the Placebo-Form group the two phases of formalin action 
are clearly distinguishable. The rubbing activity in the first (###p < 0.001) and in the fifth to 
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eleventh (##p < 0.01; ###p < 0.001) blocks was significantly higher in the Placebo-Form 
group than in the Placebo-Phys group. The PROB pre-treatment significantly reduced the 
formalin-induced nociceptive behaviour in each of the above-mentioned blocks (**p < 0.01; 
***p < 0.001) in the PROB-Form group compared to the Placebo-Form group. There was no 
significant difference between the nociceptive scores on the Placebo-Phys and PROB-Phys 
animals in any block. 
 
Since the two phases of the formalin test were clearly distinguishable, we also examined the 
nociceptive scores of the two phases separately. The nociceptive score in the Placebo-Form 
group was significantly higher during both the first and the second phase than that in the 
Placebo-Phys group (Fig 14). PROB significantly decreased the nociceptive behaviour in both 
phases (Fig 14). 
 
 
Figure 14.  
Diagrams showing the nociceptive scores in the first and the second phase. In the Placebo 
group, the formalin injection (Placebo-Form) induced a significant increase in rubbing 
activity in both the first and the second phase (***p < 0.001) as compared with the saline-
treated animals (Placebo-Phys). In both phases, pre-treatment with PROB had a significant 
effect on mitigating the formalin-induced nociceptive behaviour (**p < 0.01; ***p < 0.001) 
as compared with the Placebo-Form group. 
 
C-Fos immunohistochemistry revealed that in the Placebo-Form group, unilateral 
formalin injection produced an increase in the number of c-Fos-IR neurones in the dorsal, 
superficial area of the transverse sections of the ipsilateral TNC as compared with the non-
treated contralateral side (Fig 15 A). This increase was significant at different levels along the 
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rostrocaudal axis (between -0.3 and -3.3 mm from the beginning of the TNC), in accordance 
with the somatotopic representation of the injected area (Fig 15 C).  
 
Figure 15. 
C-Fos-IR neurones (black arrow) in the superficial laminae of a transverse section of the TNC 
in the Placebo-Form group (A). Formalin injection resulted in a higher number of c-Fos-IR 
neurones on the ipsilateral side compared to the contralateral side. Scale bar: 500 µm. (B) c-
Fos-IR neurones on the formalin-treated ipsilateral sides of sections in the TNC in the 
Placebo-Form and PROB-Form groups. The formalin-induced increase in IR cells was more 
prominent in the Placebo-Form group (B/a) than in the PROB (B/b) pretreated animals. Scale 
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bar: 200 µm. (C) Diagram showing the mean number of c-Fos IR cells in the superficial 
laminae of the TNC at different levels along the rostrocaudal axis (mean ± S.E.M, n=9 per 
group). In the Placebo-Form group, formalin produced a significantly higher number of c-
Fos-IR neurones on the formalin-treated side of the TNC as compared with the contralateral 
side at levels between -0.3 and -3.3 mm, in accordance with the somatotopic representation 
(**p < 0.01; ***p < 0.001). PROB pre-treatment significantly decreased the effect of formalin 
between -0.3 and -2.4 mm (#p < 0.05; # #p < 0.01; # # #p < 0.001). 
 
In the PROB-Form group, the number of c-Fos-IR neurones at the different levels 
along the rostrocaudal axis also increased in the ipsilateral TNC. This effect was similar, but 
less pronounced than that in the Placebo-Form group (Fig 15 B), i.e. PROB significantly 
decreased the formalin-related activation of the second order trigeminal neurones at several 
levels of the TNC (between -0.3 and -2.4 mm; Fig. 15 C). On the contralateral sides of the 
TNCs, no significant differences were noted either between the groups or between the 
different levels along the rostrocaudal axis (Fig 15).  
The nNOS immunohistochemistry resulted in neurones showing cytoplasmic and 
dendritic staining. The formalin injection gave rise to an increase in the number of nNOS-IR 
neurones in the superficial area of the ipsilateral TNC compared to the non-treated 
contralateral side in the Placebo-Form group (Fig 16 A). Along the rostrocaudal axis, 
significant increase can be observed at different levels (between -2.1 and -2.7 and between -
3.3 and -3.9 mm; Fig 16 C). In the PROB-Form group, there was no difference in the number 
of nNOS-IR neurones between ipsilateral and contralateral TNC (Fig 16 B), PROB 
significantly decreased the number of the second order trigeminal neurones expressing nNOS 
at several levels of the TNC after formalin injection (between -2.1 and -2.7 and between -3.3 
and -3.9 mm; Fig 16 C). On the contralateral sides of the TNCs, no significant differences 
were noted either between the subgroups or between the different levels along the 
rostrocaudal axis (Fig 16). 
The Western blot analysis of the TNC segments did not show significant difference 
between the contra- and ipsilateral sides for any of the groups in IL-1β (data not shown), 
which means that IL-1β expression did not change four hours after the formalin injection and 
PROB pre-treatment did not have any modulatory effect on the expression of IL-1β. 
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Figure 16. 
nNOS immunostained sections of the TNC (A/a;b Placebo-Form; A/c;d PROB-Form). Black 
arrow shows a nNOS IR neurone in the TNC. More nNOS-IR neurones can be observed on 
the ipsilateral side (A/b), than on the contralateral side (A/a) in the Placebo-Form group. 
Comparing the ipsilateral sides of the two groups, fewer nNOS-IR cells can be found in the 
PROB-Form group ((A/b);(A/d)). There is no difference between the contralateral sides. Scale 
bar: 200 µm. (B) Diagram showing the mean number of nNOS-IR cells in the TNC at 
different levels along the rostrocaudal axis (mean ± S.E.M). Formalin produced a significant 
increase in number of nNOS-IR neurones on the formalin-treated side as compared with the 
contralateral side at different levels (between -2.1 and -2.7 and between -3.3 and -3.9 mm; *p 
< 0.05; **p < 0.01). The effect of formalin was significantly decreased by pre-treatment with 
PROB between -2.1 and -2.7 and between -3.3 and -3.9 mm (#p < 0.05; # #p < 0.01). There 
was no significant difference between the contralateral sides. 
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Discussion 
 
ESTG has a direct effect on the primary trigeminal sensory neuron causing alterations 
in both the peripheral and the central endings. In the periphery, mediators from the nerve 
terminals around the meningeal vessels are released, which results in plasma protein 
extravasation and eventually neurogenic inflammation (15). In the central arm, there is a 
marked activation of the second-order neurones in the TNC (90). Our results are in 
accordance with these previous findings as we found marked increase in the number of c-Fos 
IR cells in the ipsilateral TNC both two and four hours after stimulation. This pronounced 
increase may arise directly from the electrical stimulation, or is a secondary phenomenon 
originating from the periphery due to the triggered dural extravasation and inflammation (15).  
We were interested in the activation pattern of the migraine generator nuclei after 
ESTG, to examine if this model is suitable for mimicking the functional pattern of these 
nuclei observed in human spontaneous migraine attacks. 
We found a significant increase in neuronal activity in the NRM in the two hour 
survival group, which persisted even four hours after the stimulation. Direct TNC projections 
to the NRM are sparse (91), and the superficial laminae, which are mainly activated in 
response to electrical stimulation, display even fewer connections to the NRM (92); 
accordingly activation of the TNC may not evoke a direct NRM activation. This hypothesis is 
further supported by the fact that we did not find any correlation between the increased cell 
activities in the two nuclei neither after 2 nor after 4 hours, suggesting that the activation of 
the NRM may not be a direct consequence of the activation of the TNC. Although, there is no 
correlation between the activation patterns of these two nuclei, the increase in their activity is 
present simultaneously at both 2 and 4 hours after stimulation. 
The NRM is thought to be the main output of the descending pain modulatory system, 
providing dense innervations to the spinal cord dorsal horn and to the spinal trigeminal nuclei. 
We assume that the increased c-Fos IR of the NRM may be a consequence of the activation of 
this system, and could result from the cortical and thalamic input of the NRM, or it could 
originate from the PAG (91). 
No change in the number of c-Fos immunoreactive nuclei was noticed in any region of 
the PAG. There is a direct connection between the TNC and the PAG, thus it is surprising that 
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a strong stimulus like we applied caused no alteration in this area. Previous studies indicated 
an increase in activity of the PAG after nociceptive stimulation (93), although the stimulation 
parameters and settings differed from those we applied. 
Activity of the cells in the LC did not change, however the activity of this nucleus was 
already pronounced in the sham group two hours after the stimulation, suggesting that the 
surgical procedure itself may obscure the changes caused by the electrical stimulation. After 
four hours of survival the c-Fos IR level of the LC is decreased both in the sham and 
stimulated groups, indicating that the activation of the LC is due to the invasive procedure. 
There is no evidence that the TNC projects directly to the DR (94). The DR forms part 
of the pain modulatory system (37), and receives dense afferents from the NRM, but cortical 
input can also modulate the activity of this nucleus (94). We did not find significant change in 
the number of c-Fos IR cells in the DR after ESTG. Our results suggests that the activation of 
the trigeminal system does not cause the activation of the DR, thus in the rat this nucleus may 
not participate in the short-term regulation of trigeminal nociceptive processing. 
If it is assumed that the changes seen in our experiments are secondary, the lack of 
direct projections from the TNC to most of the above-mentioned nuclei supports this 
hypothesis. In this concept, the stimulation activates the ascending nociceptive routes to the 
thalamus and to the cortex, and these structures react to the nociceptive input by activating the 
descending modulatory system. After trigeminal stimulation, the examined nuclei failed to 
exhibit the uniform activation detected during a migraine attack suggesting that this activation 
pattern of the migraine generator nuclei may be exclusively present in migraine.  
Numerous stimulation parameters and stimulation times have been applied in previous 
experiments, and we therefore decided to make use of two stimulation procedures, a short, 
mild stimulation and a longer, robust stimulation, in order to examine the possible effects of 
P2X7-R antagonism on trigeminal activation. As P2X7-R blockade was previously found to 
be effective in inflammatory conditions, we additionally examined the effects of BBG in a 
model of orofacial inflammation, the orofacial formalin test. 
Mild, short ESTG has been reported to lead to activation of the trigeminal system (54), 
and this was supported by our results.  
We observed a similar pattern in the robust stimulation paradigm, the number of c-Fos 
IR cells increasing profoundly in the TNC, indicating the activation of the trigeminal system. 
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The main difference seen between the two paradigms was in the number of cells 
activated after stimulation. Following the robust stimulation procedure more c-Fos IR cells 
were found in the TNC, suggesting a higher degree of activation than in the mild stimulation 
procedure. This increased activation may be attributed to the higher frequency applied in the 
robust paradigm, which can lead to the more rapid firing of the primary trigeminal neurons. 
An increased firing rate may cause elevated levels of transmitter release at both central and 
peripheral terminals, resulting in a higher degree of activation at the TNC level (87). It is also 
plausible that the longer stimulation interval leads to more primary cells being activated in the 
trigeminal ganglion, and hence in the TNC. We assume that in our experimental setting both 
the increased frequency and the increased stimulation interval contributed to the higher 
activation level in the TNC.  
Pre-treatment with the P2X7-R antagonist BBG was effective only in the robust 
stimulation paradigm, resulting in a decrease of the activity, reflected by the c-Fos expression. 
P2X7-Rs can be found in the trigeminal system, both in the ganglion (95) and in the TNC 
(96), therefore BBG may modulate peripheral and central processes. BBG could modulate the 
nociceptive processing by interfering with the peripheral neurogenic inflammation, or by 
modulating non-synaptic communication within the ganglion (97). At the central level, BBG 
could affect P2X7-Rs on central presynaptic terminals and modulate glutamate release (96), 
and thereby influence nociceptive transmission. Presumably, after the robust stimulation, 
where the more pronounced peripheral activation and more severe inflammation also involve 
P2X7-Rs, the blocking effect of BBG manifests, while in the mild paradigm due to the minor 
changes the effect of BBG does not emerge.  
Neither the mild nor the robust stimulation procedure caused alterations in the levels 
of CGRP. It was earlier found that ESTG with parameters similar to our robust stimulation, 
led to the depletion of CGRP from the medial one-third of the central terminals of the 
trigeminal afferents (98). However, those examinations were conducted immediately after 
stimulation of the trigeminal ganglion, whereas in our experiments a 2 or a 4 hour survival 
time was included for better observability of the activity changes (c-Fos). These periods might 
be sufficient for the depleted CGRP to be resynthesized and for the changes in CGRP-
immunoreactivity seen immediately after stimulation to normalize. BBG treatment did not 
modify the levels of CGRP in either the sham or the stimulated group. 
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The injection of formalin into the whisker pad causes a biphasic behavioural effect 
(56), as seen in our experiments also. BBG did not exhibit any effect in the first phase of the 
formalin response. When formalin was applied to the hind paw and was combined with a 
selective P2X7-R antagonist, A-438079, in previous work, protective effect was exerted only 
in the second phase of the formalin test (66). Furthermore, BBG was earlier shown to be 
hyperalgesic in the modulation of acute nociception in the hot-plate test (62). These results 
suggest that BBG and blockade of the P2X7-Rs may not be effective against acute 
nociception. 
In the second phase of the formalin test, BBG did not demonstrate any obvious effect. 
At the beginning of the second phase (in blocks 5-7), the nociceptive scores revealed a 
decreasing tendency, while in the later blocks the opposite could be observed. Since another 
P2X7-R antagonist was effective when formalin was applied at the hind paws, our results 
suggest that the role of the P2X7-Rs in the sensory system is not uniform.  
Four hours after formalin injection, c-Fos immunohistochemistry revealed that the 
TNC displays clear activation. The pattern of activation corresponds to the somatotopic 
projection pattern of the injected area. BBG had no effect on the activation of the trigeminal 
system after formalin. Our results in the orofacial formalin test are somewhat surprising, 
considering that other antagonists of the P2X7-Rs (65, 66, 99) and even BBG (62) have 
proven effective in numerous inflammatory models. However, none of these experiments 
related to the trigeminal system, and our results are the first regarding the effects of blockade 
of the P2X7-Rs by BBG in this area after inflammation caused by formalin. 
The levels of CGRP were not altered 4 hours after formalin injection, and following 
treatment with BBG. Alterations in CGRP usually occur immediately during or after the 
applied stimulus and cease within a matter of hours (47, 100), and our results are in line with 
this. The effect of P2X7-R antagonism on the expression of CGRP in the formalin test should 
be further elucidated with regard to the time scale. 
BBG in the micromolar range was previously shown to inhibit voltage-dependent 
sodium channels in vitro (101), and it might therefore be possible that this feature of BBG 
contributes to its effects in our experiments. This is rather unlikely, considering that we 
applied BBG in a single dose, which has been shown not to reach micromolar levels even 
after continuous administration in mice (102). 
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Our results suggest that P2X7-Rs have a role in the modulation of trigeminal 
nociceptive processing. Further investigations of the relations of the trigeminal system and 
P2X7-R signalling may provide important details concerning trigeminal nociceptive functions 
and the pathomechanism of headaches. 
In our experiments PROB produced a pronounced antinociceptive behavioural effect 
in the orofacial formalin test especially in the second phase. PROB exhibited no effect on the 
baseline activity of the control animals, which received a saline injection in the whisker pad. 
In addition to the modulation of the nociceptive behaviour, PROB also mitigated the formalin 
induced c-Fos and nNOS expression in the TNC – considered markers of activation and 
sensitization of these neurons (103, 104).  
Previously PROB proved to be effective also after systemic nitroglycerin 
administration, decreasing the levels of sensitization markers and modulating CGRP levels in 
the TNC (105). The antinociceptive effect of PROB along with its inhibitory effect on the 
trigeminal activation and sensitization can be the result of various mechanisms:  
PROB inhibits MRP4 (75), which releases key inflammatory mediators such as PGE1 
and PGE2 from cells in a time- and ATP-dependent manner (76). PGE2 can sensitize transient 
receptor potential channel subtype V member 1 (TRPV1) (106), a key factor in the 
development of sensitization during nociception (107). Moreover, PGE2 can induce CGRP 
release from cultured trigeminal ganglion cells (108). PGE2 can also act on the central site of 
the trigeminal system by enhancing the capsaicin-induced CGRP release in slice preparations 
of the TNC (109). The expression of cyclooxygenase-2, the inducible enzyme of 
prostaglandin synthesis (110) has also been detected in the neurones and glial cells in the 
trigeminal ganglion (111) and in the neurones of the TNC (112). In addition, prostaglandin 
receptors are present in the trigeminal ganglion (113), co-expressed with TRPV1, with a 
functional interaction between them in the trigeminal system (114, 115), and are involved in 
mediating CGRP release from cultured rat trigeminal neurones (116). Quantitative 
autoradiography has revealed that TNC has a moderate density of PGE2 binding sites as well 
(117). Accordingly, a possible mechanism of action of PROB is the inhibition of the release 
of PGE2, a key player in trigeminal nociception and an important molecule in migraine 
genesis (118) through the blockade of MRP4.  
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Data suggest that PROB is able to activate some of the transient receptor potential 
channels, including TRPV2 and TRPA1 (77, 78) which play an important role in pain 
perception (79, 80) and are present in the trigeminal system (119, 120). However, the agonist-
mediated desensitization of these receptors is also known (77, 81), which can cause an 
antinociceptive effect (121, 122). PROB can desensitize the TRPA1 (77) and may act 
similarly on TRPV2 as well, which might account of its antinociceptive properties in the 
present experiments.  
PROB also inhibits the PANX1 (82), which is expressed at several sites in the central 
nervous system (123); and is crucial in caspase-1 activation leading to the production and 
release of IL-1β in neurones, astrocytes and macrophages (83, 84). The release of IL-1β from 
trigeminal ganglion satellite cells may contribute to the mechanisms underlying trigeminal 
inflammatory hyperalgesia (124). Up-regulation of astrocytic IL-1β in the TNC can lead to 
central sensitization via its receptors present on trigeminal neurones in the same area (125, 
126). These results clearly indicate that IL-1β plays a role in trigeminal activation. However 
the results of our Western blot measurement showed that there were no changes in the 
expression of IL-1β at the level of TNC four hours after formalin administration and 
suggesting that PROB may not influences IL-1β in the TNC, but one can not exclude the 
possibility that PROB affects IL-1β in the peripheral sites of the trigeminal system.  
PROB can increase the concentration of kynurenic acid, an endogenous tryptophan 
metabolite (127) in the central nervous system (128). This phenomenon can be caused by 
inhibition of organic anion transporters by PROB (129, 130), which are involved in the 
transport of kynurenic acid from brain through the blood-brain barrier (131) or by increasing 
of concentration of tryptophan in the central nervous system (132). Experimental data suggest 
that kynurenic acid can affect nociception (133-135) and elevation in its concentration in the 
brain can inhibit the trigeminal activation (136, 137), probably due to an antagonistic effect 
on ionotropic glutamate receptors (138) or due an agonistic action on G-protein-coupled 
receptor-35 (139). Therefore the antinociceptive effect of PROB may be related to the 
increases in kynurenic acid concentration.  
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Conclusions 
ESTG caused clear activation only in the NRM, not in the other migraine generator 
nuclei. This activation pattern does not correspond to what was seen in migraine patients 
during the attack. The origin of the brainstem activation is not known, it can be the 
consequence of pain, but the persistent activation of these structures after headache cessation 
suggests, that the activation of these nuclei is specific for migraine (18). Our result support 
this hypothesis, as the activation of the trigeminal system not resulted in the activation of the 
migraine generator nuclei. However, the exact mechanisms of brainstem activation in 
migraine patients needs to be further elucidated. Our result in the rat demonstrate that in this 
model the functioning of the descending pain modulatory system can be studied, and the 
further characterization of molecular mechanism in the rat may provide useful information 
about headache pathomechanism. 
Blocking the P2X7-R by BBG was able to modulate trigeminal activation only after 
the robust stimulation, suggesting that the role of P2X7-Rs in trigeminal nociception is 
complex, and may depend on the stimulus applied. Similar controversial effects were 
observed in an earlier work with BBG (62), supporting that a more detailed evaluation of 
P2X7 receptor functioning in the trigeminal system is needed.  
PROB showed clear antinociceptive effect in the formalin test, and also in previous 
experiments (105), however it is not clear which of its molecular targets is responsible for this 
effect.  
Our result provide important information about the functioning of the trigeminal 
system, thus contribute to the understanding of pathological processes underlying headache 
and migraine. 
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Abstract Activation of the trigeminal system plays an
important role in the pathomechanism of headaches. A
better understanding of trigeminal pain processing is
expected to provide information helping to unravel the
background of these diseases. ATP, a key modulator of
nociceptive processing, acts on ligand-gated P2X receptors.
Antagonists of the P2X7 receptors, such as Brilliant Blue G
(BBG), have proved effective in several models of pain.
We have investigated the effects of BBG after electrical
stimulation of the trigeminal ganglion and in the orofacial
formalin test in the rat. The right trigeminal ganglion of
male rats was stimulated either with 5 Hz, 0.5 mA pulses
for 5 min (mild procedure) or with 10 Hz, 0.5 mA pulses
for 30 min (robust procedure), preceded by 50 mg/kg i.v.
BBG. The animals were processed for c-Fos and calcitonin
gene-related peptide (CGRP) immunohistochemistry. In
the orofacial formalin test, 50 lL of 1.5 % formalin was
injected into the right whisker pad of awake rats, following
the pre-treatment with BBG. Behaviour was monitored for
45 min, and c-Fos and CGRP immunohistochemistry was
performed. BBG attenuated the increase in c-Fos-positive
cells in the caudal trigeminal nucleus (TNC) after robust
stimulation, but not after mild stimulation. No alterations in
CGRP levels were found with either methodology. BBG
did not mitigate either the behaviour or the increase in
c-Fos-positive cells in the TNC during the orofacial for-
malin test. These results indicate that P2X7 receptors may
have a role in the modulation of nociception in the
trigeminal system.
Keywords Trigeminal system  P2X7 receptor 
Trigeminal ganglion stimulation  Formalin test
Introduction
Primary headaches are very common, but underdiagnosed
and undertreated neurological conditions. Even following
the correct diagnosis, the available therapeutic options
often do not provide complete resolution of the pain, and
recurrence of the headache after treatment is also a com-
mon complaint. Research is, therefore, currently focused
on gaining an understanding of the causes of different
headache disorders and developing new therapeutic
options.
A common mechanism in primary headaches involves
activation and sensitization of the trigeminal system, but
the exact mechanism of these phenomena remains to be
discovered (Tajti et al. 2011).
Recent results suggest that the purine molecule ATP has
an important role in the regulation of nociceptive trans-
mission (Burnstock 2013). Molecules targeting the speciﬁc
receptors (Rs) for ATP (P2X and P2Y-Rs) have been
proven to be effective in modulating different pain
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conditions, e.g., neuropathic and inﬂammatory pain (Ando
et al. 2010). Among the ligand-gated P2X-Rs, the P2X7
receptor (P2X7-R) has been intensively studied in different
pain states. The P2X7-R is a non-selective cation channel,
unique among the P2X-Rs by virtue of its long C terminal
domain, and its ability to open a pore permeable to mole-
cules up to 900 Da (Surprenant et al. 1996). Experiments
with knock-out mice have revealed that the absence of the
P2X7-R leads to the disappearance of mechanical and
thermal hypersensitivity in models of neuropathic and
inﬂammatory pain, whereas normal nociceptive processing
is retained (Chessell et al. 2005). P2X7-R antagonists have
been examined in similar models, and the results underline
the importance of the P2X7-R in chronic pain conditions
(Honore et al. 2006; McGaraughty et al. 2007). Results
from an acute inﬂammatory pain model suggest that the
P2X7-R may participate in the development of central
sensitization (Itoh et al. 2011), a common feature in the
trigeminal system during migraine attacks manifested by
the presence of allodynia (Burstein et al. 2000).
However, little information is available as concerns the
role of P2X7-Rs in the trigeminal system. In a model of
orofacial pain, the chronic constriction injury model,
inhibition of the P2X7-R led to a decrease in tactile allo-
dynia through a p38 MAPK-dependent mechanism (Ito
et al. 2013). Goloncser and Sperlagh recently reported that
blockade of P2X7-Rs in mice by Brilliant Blue G (BBG) [a
selective, non-competitive P2X7-R antagonist, with good
blood–brain barrier permeability (Jiang et al. 2000)]
reduced thermal hyperalgesia after systemic nitroglycerin
administration (Goloncser and Sperlagh 2014). These
results lend support to the theory that P2X7-Rs may play a
crucial part in the development of headache disorders.
Calcitonin gene-related peptide (CGRP) has an essential
role in trigeminal nociceptive processing. CGRP infusion
causes migraine-like headache in migraineurs (Hansen
et al. 2010; Lassen et al. 2002), and the levels of CGRP are
higher in migraine patients than in healthy controls (Fri-
berg et al. 1994).
Electrical stimulation of the trigeminal ganglion, an
animal model of trigeminal activation, causes plasma
protein extravasation (Markowitz et al. 1987), which can
be attenuated by drugs effective in migraine therapy
(Limmroth et al. 2001). The stimulation results in alter-
ations in the dura mater (Knyihar-Csillik et al. 1995), in the
trigeminal ganglion and in the caudal part of the spinal
trigeminal nucleus (TNC) (Knyihar-Csillik et al. 1998). In
previous investigations, various stimulation frequencies,
intensities and durations were applied. Results related to
peptide release and c-Fos expression in the TNC after the
procedure suggest that both higher frequency and higher
intensity lead to an increased stimulation of the trigeminal
ganglion cells (Samsam et al. 1999; Takemura et al. 2000).
Diverse periods of stimulation caused different morpho-
logical alterations in the CGRP-immunoreactive nerve
terminals of the dura mater, suggesting the release of
CGRP after prolonged stimulation (Knyihar-Csillik et al.
1995). Based on these previous results, we decided to
perform the electrical stimulation in two different setups: a
mild and a robust one.
Formalin applied to the whisker pad of rats (another
model of trigeminal activation) causes a biphasic beha-
vioural effect, the ﬁrst phase being caused by the direct
activation of Ad and C ﬁbres, while the second phase
reﬂects the process of inﬂammation (Porro and Cavazzuti
1993). Activation of the trigeminal system has been
demonstrated by c-Fos immunohistochemistry to be pre-
sent at the level of the TNC after the injection of formalin
(Wang et al. 1994). Both phenomena are suitable for
assessments of the inﬂuence of substances on
inﬂammation.
The aim of the present study was to examine the effects
of a P2X7-R antagonist, BBG, in the electrical stimulation
and orofacial formalin models of acute trigeminal
activation.
Materials and methods
Ethical approval
The procedures used in this study followed the guidelines
of the 8th Edition of the Guide for the Care and Use of
Laboratory Animals and the Use of Animals in Research of
the International Association for the Study of Pain and the
directive of the European Economic Community (86/609/
ECC). The experiments were approved by the Committee
of Animal Research at the University of Szeged (I-74-12/
2012) and the Scientiﬁc Ethics Committee for Animal
Research of the Protection of Animals Advisory Board
(XXIV/352/2012). Male Sprague–Dawley rats were housed
under standard laboratory conditions, on a 12-h light–dark
cycle, with tap water and rat chow available ad libitum.
The suffering of the animals and the number of animals
used were kept at a minimum.
Mild stimulation procedure
Twenty-four animals (250–300 g) were used. Half of the
animals received an intravenous (i.v.) injection of 50 mg/
kg BBG, while the other half were injected with the vehicle
of BBG, physiological saline. Two h after the BBG or
saline injection, the animals were deeply anesthetised with
chloral hydrate (400 mg/kg) and the head was secured in a
stereotaxic apparatus (Stoelting Co., Wood Dale, USA). A
hole, approximately 3 mm in diameter, was drilled into the
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right side of the skull with a dental drill, and a concentric
bipolar electrode (FHC Inc., Bowdoin, USA, CBBRE75)
was lowered to the right trigeminal ganglion. Half of the
animals from the saline-treated group (5SStim) and half of
the animals from the BBG group (5BStim) were electri-
cally stimulated for 5 min with 5 Hz, 0.5 mA, 0.5 ms delay
twin pulses generated by an Electrostimulator ST3
(Medicor Hungary). The other animals from both groups
were used as sham animals: the electrode was lowered to
the right trigeminal ganglion for 5 min, but no stimulation
was performed (5SSham and 5BSham groups). After both
procedures, the animals were returned to their home cages
and maintained under deep anaesthesia covered by a
warming blanket for 2 h.
Robust stimulation procedure
Twenty-one animals (250–300 g) were used; the treatment
and surgical procedures were identical to the previous ones,
except that the stimulation parameters of 10 Hz, 0.5 mA,
0.5 ms delay twin pulses were applied for 30 min, and the
animals were maintained under deep anaesthesia, covered
by a warming blanket, in their home cages for 4 h from the
beginning of the stimulation. In both the mild and the
robust paradigm, the jaw of the animal was twitching
during the electrical stimulation, indicating the correct
placement of the electrode.
Overview of the robust stimulation groups:
Saline ? 30-min sham: 30SSham (n = 6).
Saline ? 30-min stimulation: 30SStim (n = 5).
BBG ? 30-min sham: 30BSham (n = 4).
BBG ? 30-min stimulation: 30BStim (n = 6).
Orofacial formalin test
Behavioural tests
Rats (n = 52, 200–240 g) were injected i.v. either with
50 mg/kg BBG or with physiological saline. One hour and
ﬁfty minutes later, the animals were placed in a
30 9 30 9 30 cm box, with mirrored walls for the moni-
toring of behavioural activity. After 10 min of habituation,
the animals were taken out of the box and under minimal
restraint were injected subcutaneously with 50 lL of either
physiological saline (SSal and BSal groups) or 1.5 % for-
malin (SForm and BForm groups) to the right whisker pad.
After the injection, they were returned immediately to the
box and their behaviour was monitored for 45 min under
video surveillance. The injection of formalin causes a
behavioural response, which consists in rubbing and
scratching of the injected whisker pad with the ipsilateral
fore- or hindpaw. The rate of this behaviour correlates with
the pain sensation caused by formalin (Clavelou et al.
1989). The 45-min period was divided into 15 9 3-min
blocks, and the total time spent rubbing the injected
whisker pad, measured in seconds, was taken as the noci-
ceptive score in the given block. The normal grooming
activity of the saline-treated animals was measured as
control. After the monitoring period, the animals were
returned into their home cages and maintained under
standard laboratory conditions until perfusion, which was
performed under deep chloral hydrate anaesthesia 4 h after
the whisker pad injections.
Immunohistochemistry
Animals were perfused with 0.1 M phosphate-buffered
saline (PBS), followed by 4 % paraformaldehyde in 0.1 M
phosphate buffer. The whole brain and the upper cervical
spinal cord were removed and postﬁxed overnight in the
same ﬁxative. The correct placement of the electrode was
checked during autopsy, the electrode was in the ganglion
in all cases. Cryoprotection was performed, using gradient
sucrose solutions up to 30 %. Sections from the TNC were
prepared from the block, ranging from 1 mm rostral to
4 mm caudal from the obex, and the ventral part of the
control (left) side of the blocks was marked by a small
incision to enable side discrimination on the sec-
tions. 30 lm thick transverse sections were cut and serially
collected in 18 wells containing PBS with 0.1 % sodium
azide, the overall distance therefore being 540 lm between
consecutive sections. Free-ﬂoating sections were immersed
in 0.3 % H2O2 in PBS to block endogenous peroxidase
activity. After several washes in PBS containing 1 % Tri-
ton X-100 (PBS-T), they were incubated for 1 h in PBS-T
containing 10 % normal goat serum. The sections were
then incubated overnight at room temperature in the pri-
mary antibody for c-Fos (1:2000, Santa Cruz Biotechnol-
ogy, sc-52) or CGRP (1:20,000, Sigma-Aldrich C8198).
The immunohistochemical reaction was visualised by
using the Vectastain Elite avidin–biotin kit (PK6101;
Vector Laboratories,) with 3,30-diaminobenzidine as chro-
mogen (Sigma-Aldrich) intensiﬁed with nickel ammonium
sulphate (Scharlau Chemie). The speciﬁcity of the immune
reactions was veriﬁed by omitting the primary antisera.
Sections were mounted onto glass slides, air-dried and
coverslipped with DPX mounting medium (Scharlau Che-
mie). On the basis of anatomical observations, sections
from the same rostro-caudal level were compared during
the statistical evaluation.
An observer blinded to the treatment procedures used a
Nikon Optiphot-2 light microscope under a 209 objective
to count cells immunopositive for c-Fos. The whole area of
the laminae I-II in each section of the TNC was evaluated
and counted.
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CGRP-stained sections were photographed with a Zeiss
AxioCam MRc Rev.3 digital camera attached to a Zeiss
AxioImager M2 microscope. Digital images were taken
with a 209 objective in TNC laminae I–II, and the area
covered by CGRP-immunoreactive ﬁbres was measured
through the use of ImageProPlus 6.2 software (Media
Cybernetics Inc.) by an observer blinded to the treatment
procedures.
Statistical analysis
The cell count results were aligned according to the rostro-
caudal location of the section as mentioned above. Data
from different levels of the TNC were handled separately,
and analysed by two-way repeated measures ANOVA. The
group was used as the between-subject factor and the levels
(-13.89, -14.43, -14.97, -15.51, -16.05, -16.59,
-17.13, -17.67, -18.21 mm from bregma) as the within-
subject factor for the analysis.
When Mauchly’s test of sphericity proved to be signif-
icant, the Greenhouse-Geisser correction was performed.
Pairwise comparisons of group means were performed on
the basis of estimated marginal means with Sidak adjust-
ment for multiple comparisons.
The sums of the areas covered by CGRP-immunoreac-
tive ﬁbres were compared between groups according to the
Fig. 1 Summary of the results
from the mild stimulation
paradigm regarding c-Fos
immunostaining. Representative
photos from the right sides of
the four treatment groups after
c-Fos immunohistochemistry,
taken at 16.05 mm caudally
from bregma: a 5SSham,
b 5SStim, c 5BSham, d 5BStim.
Scale bar 200 lm.
Diagram showing the number of
c-Fos-immunoreactive cells
across the different levels of the
TNC after mild electrical
stimulation of the trigeminal
ganglion (group mean ± SEM)
(e). There was no signiﬁcant
difference between the control
(left) sides (data not shown). For
clarity, only the control side of
the saline-treated stimulated
group is presented. The
hashmarks indicate signiﬁcance
in the comparison of the right
sides of the 5SSham and 5SStim
groups at different levels of the
TNC (#p\ 0.05; ##p\ 0.01;
###
p\ 0.001). BBG treatment
showed an attenuating tendency,
though it proved to be
signiﬁcant merely at the level of
-13.89 mm (**p\ 0.01,
5SStim–5BStim)
Z. Boha´r et al.
123
different levels, two-way repeated measures ANOVA
being used as detailed above.
Nociceptive scores from the behavioural study were
compared block by block through two-way repeated mea-
sures ANOVA. Groups were used as between-subject
factor and blocks (1–15) as within-subject factor for the
analysis. Other statistical parameters were identical to
those mentioned above.
Statistical analyses were carried out with IBM SPSS
Statistics, version 20 (IBM Corporation) software. All tests
were two-sided, and p\ 0.05 was considered to be statis-
tically signiﬁcant. Graphs were prepared by using Sig-
maPlot 12.0 (Systat Software Inc.). Data are reported as
mean ± SEM.
Results
Mild stimulation procedure
As a signiﬁcant interaction was found between the two
investigated factors (levels and groups, p\ 0.01) for the
number of c-Fos-immunoreactive cells in the mild stimu-
lation paradigm, both effects could not be reported inde-
pendently, whereas the group differences could be
examined separately across different levels on the basis of
the estimated marginal means for multiple comparisons.
Lowering of the electrode to the trigeminal ganglion for
5 min without stimulation (5SSham group) did not cause
any signiﬁcant change in the number of c-Fos-immunore-
active cells in the TNC relative to the control side. The
comparisons of the cell numbers from the control (left)
sides for each of the four treatment groups did not reveal
any signiﬁcant changes (data not shown), and therefore
only the data for the stimulated (right) sides of the groups
are presented in Fig. 1a–d. Electrical stimulation of the
ganglion caused a signiﬁcant increase in the number of
c-Fos-immunoreactive (IR) cells along the whole extent of
the examined region of the TNC (Fig. 1a, b, e). BBG
exhibited a signiﬁcant effect (p\ 0.01) compared with the
saline-treated stimulated animals only at the level of
-13.89 mm from bregma (Fig. 1b, c, e).
A signiﬁcant interaction was found between the groups
and levels, when the area values from the CGRP mea-
surements were examined. However, the comparisons of
the groups and stimulated-control sides at different levels
did not reveal any signiﬁcant alteration (Fig. 2).
Robust stimulation procedure
A signiﬁcant interaction was not found between the
investigated factors of levels and groups for the number of
c-Fos IR cells in the robust stimulation paradigm. The
levels had a signiﬁcant effect (p\ 0.001), and there was
also a signiﬁcant difference between the groups
(p\ 0.001). Pairwise comparisons revealed that there was
no signiﬁcant difference between the control sides of the
four treatment groups (data not shown). Lowering of the
electrode without stimulation did not cause signiﬁcant
changes in the number of c-Fos IR cells in either sham-
treated group as compared with the control (Fig. 3e,
30SSham and 30BSham with the 30SStim control side).
Robust stimulation caused a marked increase in the number
of c-Fos IR cells in the saline-treated animals (Fig. 3a, b, e,
30SStim compared with 30SSham, #p\ 0.001). BBG had
a signiﬁcant attenuating effect on this increase (Fig. 3b, d,
e, 30SStim compared with 30BStim).
CGRP expression was not altered by stimulation or
BBG administration in any of the animal groups (Fig. 4).
Orofacial formalin test
A signiﬁcant interaction was found between time and
groups (p\ 0.05) during the analysis of the behavioural
data from the orofacial formalin test. The pairwise com-
parison revealed that the nociceptive scores of the saline-
injected groups (SSal and BSal) did not differ from each
other at any time point (Fig. 5). The injection of formalin
caused a signiﬁcant increase in the nociceptive scores in
blocks 1 and 5–7 (Fig. 5, SForm compared with SSal).
After the injection of formalin into the whisker pad, the
BBG-treated animals demonstrated signiﬁcantly increased
nociceptive scores in blocks 1, 6 and 8 as compared with
the control (Fig. 5, $p\ 0.05). The BBG-treated animals
spent less time rubbing their formalin-injected side in both
Fig. 2 Diagram showing the area covered by CGRP-immunoreactive
ﬁbres at the different levels of the TNC in the different treatment
groups after mild electrical stimulation of the trigeminal ganglion
(group mean ± SEM). There was no signiﬁcant difference between
either the control or the stimulated sides or the different groups. For
clarity, only the control side of the saline-treated stimulated group is
presented
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blocks 1 and 5–7, but this difference was not signiﬁcant
compared with the SForm group. In block 8, BBG-treated
animals spent signiﬁcantly more time rubbing their whisker
pad as did the animals in the formalin group (Fig. 5). In
our experiments, the second phase of the formalin test
subsided more quickly as expected in the SForm group,
while it was more prolonged in the BForm group, and this
difference may account for the signiﬁcant effect of BBG in
block 8.
A signiﬁcant interaction was observed between the
levels and groups (p\ 0.001) for the number of c-Fos IR
cells in the orofacial formalin test. There was no signiﬁcant
difference when either the control (left) sides or the control
and saline-injected sides were compared at any level
(Fig. 6e). The injection of formalin increased the number
of c-Fos-IR cells signiﬁcantly at the levels -16.59 to
-15.51 mm, mainly in the central part of the TNC as
compared with the saline-injected side in the SSal group. In
the BForm group, a similar pattern was observed, except
that the difference involved one additional level
(-14.97 mm, Fig. 6e). There was no signiﬁcant difference
between the SForm and BForm groups at any level
(Fig. 6b, d).
No group difference was found in any of the measured
parameters as regards the CGRP immunoreactivity
(Fig. 7).
Fig. 3 Summary of the results
from the robust stimulation
paradigm regarding c-Fos
immunostaining. Representative
photos from the right sides of
the four treatment groups after
c-Fos immunohistochemistry,
taken at 16.05 mm caudally
from bregma: a 30SSham,
b 30SStim, c 30BSham,
d 30BStim. Scale bar 200 lm.
Diagram showing the number of
c-Fos-immunoreactive cells at
different levels along the rostro-
caudal axis in the TNC (group
mean ± SEM) in the robust
stimulation paradigm (e). There
was no signiﬁcant difference
between the control sides (data
not shown). For clarity, only the
control side of the saline-treated
stimulated group is presented.
Electrical stimulation of the
right trigeminal ganglion caused
a signiﬁcant increase in the
number of c-Fos-positive cells
as compared with the right side
of the sham group at all levels
examined (###p\ 0.001
30SSham–30SStim). BBG
treatment had a signiﬁcant
decreasing effect on the cell
counts (***p\ 0.001 30SStim–
30BStim)
Z. Boha´r et al.
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Discussion
Numerous stimulation parameters and stimulation times
have been applied in previous experiments, and we there-
fore decided to make use of two stimulation procedures, a
short, mild stimulation and a longer, robust stimulation, in
order to examine the possible effects of P2X7-R antago-
nism on trigeminal activation. As P2X7-R blockade was
previously found to be effective in inﬂammatory condi-
tions, we additionally examined the effects of BBG in a
model of orofacial inﬂammation, the orofacial formalin
test.
Mild, short electrical stimulation of the trigeminal
ganglion has been reported to lead to activation of the
trigeminal system (Takemura et al. 2000), and this was
supported by our results. The activation may be direct,
stemming from depolarization of the central terminals of
the primary trigeminal afferents, or it may be indirect,
resulting from the release of peripheral mediators (his-
tamine, bradykinin, substance P or CGRP).
We observed a similar pattern in the robust stimulation
paradigm, the number of c-Fos IR cells increasing pro-
foundly, indicating the activation of the trigeminal system.
The main difference seen between the two paradigms
was in the number of cells activated after stimulation.
Following the robust stimulation procedure more c-Fos IR
cells were found in the TNC, suggesting a higher degree of
activation than in the mild stimulation procedure. This
higher degree of activation may be attributed to the higher
frequency applied in the robust paradigm, which can lead
to the more rapid ﬁring of the primary trigeminal neurons.
An increased ﬁring rate may cause increased levels of
transmitter release at both central and peripheral terminals,
resulting in a higher degree of activation at the TNC level
(Samsam et al. 1999). It is also plausible that the longer
stimulation interval leads to more primary trigeminal cells
being activated in the TG, and hence in the TNC. We
assume that in our experimental setting both the increased
frequency and the increased stimulation interval con-
tributed to the higher activation level in the TNC.
Pre-treatment with the P2X7-R antagonist BBG was
effective only in the robust stimulation paradigm, resulting
in a decrease of the activity, reﬂected by the c-Fos
expression. P2X7-Rs can be found in the trigeminal sys-
tem, both in the ganglion (Teixeira et al. 2010) and in the
TNC (D’Amico et al. 2010), therefore BBG may modulate
peripheral and central processes. BBG could modulate the
nociceptive processing by interfering with the peripheral
neurogenic inﬂammation, or by modulating non-synaptic
communication within the ganglion (Matsuka et al. 2001).
At the central level, BBG could affect P2X7-Rs on central
presynaptic terminals and modulate glutamate release
(D’Amico et al. 2010), and thereby inﬂuence nociceptive
transmission. Presumably, after the robust stimulation,
where the more pronounced peripheral activation and more
severe inﬂammation also involve P2X7-Rs, the blocking
effect of BBG manifests, while in the mild paradigm due to
the minor changes the effect of BBG does not emerge.
Neither the mild nor the robust stimulation procedure
caused alterations in the levels of CGRP. It was earlier
found that electrical stimulation of the trigeminal ganglion
Fig. 4 Diagram showing the area covered by CGRP-immunoreactive
ﬁbres at the different levels of the TNC in the different treatment
groups after robust electrical stimulation of the trigeminal ganglion
(group mean ± SEM). There was no signiﬁcant difference between
either the control or the stimulated sides or the different groups. For
clarity, only the control side of the saline-treated stimulated group is
presented
Fig. 5 Diagram showing the mean nociceptive scores in different
time blocks from the four treatment groups (group mean ± SEM,
n = 13) in the orofacial formalin test. The injection of formalin
increased the nociceptive score in blocks 1 and 5–7 as compared with
the saline-injected animals (#p\ 0.05, ##p\ 0.01). BBG treatment
did not affect the nociceptive scores after saline injection, and did not
modify the normal behaviour. The nociceptive scores of the BBG and
saline-treated formalin-injected groups did not differ signiﬁcantly in
any block
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with parameters similar to our robust stimulation, led to the
depletion of CGRP from the medial one-third of the central
terminals of the trigeminal afferents (Knyihar-Csillik et al.
1998). However, those examinations were conducted
immediately after stimulation of the trigeminal ganglion,
whereas in our experiments a 2 or a 4 h survival time was
included for better observability of the activity changes (c-
Fos). These periods might be sufﬁcient for the depleted
CGRP to be resynthesised and for the changes in CGRP
immunoreactivity seen immediately after stimulation to
normalise. BBG treatment did not modify the levels of
CGRP in either the sham or the stimulated group.
The injection of formalin into the whisker pad causes a
biphasic behavioural effect (Clavelou et al. 1989), as also
seen in our experiments. The ﬁrst short and intense phase is
thought to be caused by the immediate activation of the Ad
and C ﬁbres and may be referred as acute pain. The second
phase is less intense, but prolonged, and probably caused
by sensitization of the trigeminal system due to the
inﬂammatory processes occurring at the periphery. BBG
did not exhibit any effect in the ﬁrst phase of the formalin
response. When formalin was applied to the hind paw and
was combined with a selective P2X7-R antagonist,
A-438079, in previous work, protective effect was exerted
only in the second phase of the formalin test (McGaraughty
et al. 2007). Furthermore, BBG was earlier shown to be
hyperalgesic in the modulation of acute nociception in the
hot-plate test (Ando et al. 2010). These results suggest that
Fig. 6 Summary of the results
from the orofacial formalin test
regarding c-Fos
immunostaining. Representative
photos from the right (injected)
sides of the four treatment
groups after c-Fos
immunohistochemistry taken at
16.05 mm caudally from
bregma: a SSal, b SForm,
c BSal, d BForm. Scale bar
200 lm. Diagram showing the
mean number of c-Fos
immunoreactive cells along the
rostro-caudal axis in the TNC in
the orofacial formalin test
(group mean ± SEM) (e).
Injection of saline did not cause
any increase in the number of
c-Fos-positive cells (SSal and
BSal groups). The effect of
formalin was visible only on the
injected side; the control sides
were similar to those in the
saline-injected controls. For
clarity, only the control side of
the SForm animals is presented.
Formalin caused an increase in
c-Fos cell number on the
ipsilateral side as compared
with the saline-injected side of
the controls (SForm compared
with SSal), signiﬁcant at the
levels -16.59 to -15.51 mm
(###p\ 0.001). In the BBG-
treated rats, formalin had a
similar activity-increasing
effect, signiﬁcant at the levels
-16.59 to -14.97 mm
($p\ 0.05; $$p\ 0.01;
$$$p\ 0.001). The groups
SForm and BForm did not differ
signiﬁcantly from each other
Z. Boha´r et al.
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BBG and blockade of the P2X7-Rs may not be effective
against acute nociception.
In the second phase of the formalin test, BBG did not
demonstrate any obvious effect. At the beginning of the
second phase (in blocks 5–7), the nociceptive scores
revealed a decreasing tendency, while in the later blocks
the opposite could be observed. Since another P2X7-R
antagonist was effective when formalin was applied at the
hind paws, our results suggest that the role of the P2X7-Rs
in the sensory system is not uniform.
Four h after formalin injection, c-Fos immunohisto-
chemistry revealed that the TNC displays clear activation.
The pattern of activation corresponds to the somatotopic
projection pattern of the injected area. BBG had no effect
on the activation of the trigeminal system after formalin.
Our results in the orofacial formalin test are somewhat
surprising, considering that other antagonists of the P2X7-
Rs (Borsani et al. 2010; Honore et al. 2006; McGaraughty
et al. 2007) and even BBG (Ando et al. 2010) have proven
effective in numerous inﬂammatory models. However,
Fig. 7 Summary of the results
after CGRP immunostaining in
the orofacial formalin test.
Representative photos of CGRP
immunohistochemistry on the
right sides of the TNC from the
four treatment groups taken at
14.97 mm caudally from
bregma a 5SSham, b 5SStim,
c 5BSham, d 5BStim. Scale bar
200 lm. Diagram showing the
area covered by CGRP-
immunoreactive ﬁbres at the
different levels of the TNC in
the different treatment groups in
the orofacial formalin test
(group mean ± SEM) (e).
There was no signiﬁcant
difference between either the
control or injected sides or the
different groups. For clarity,
only the control side of the
saline-treated formalin-injected
group is presented
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none of these experiments related to the trigeminal system,
and our results are the ﬁrst regarding the effects of
blockade of the P2X7-Rs by BBG in this area after
inﬂammation caused by formalin.
The levels of CGRP were not altered 4 h after formalin
injection, and following treatment with BBG. Alterations
in CGRP usually occur immediately during or after the
applied stimulus and cease within a matter of hours (Buzzi
et al. 1991; Greco et al. 2008), and our results agree with
this. However, in the nitroglycerin model, changes in
CGRP immunoreactivity were seen 4 h after nitroglycerin
administration, suggesting that the alterations in CGRP
levels can be long-term. The effect of P2X7-R antagonism
on the expression of CGRP in the formalin test should be
further elucidated with regard to the time scale.
BBG in the micromolar range was previously shown to
inhibit voltage-dependent sodium channels in vitro (Jo and
Bean 2011), and it might, therefore, be possible that this
feature of BBG contributes to its effects in our experi-
ments. This is rather unlikely, considering that we applied
BBG in a single dose, which has been shown not to reach
micromolar levels even after continuous administration in
mice (Diaz-Hernandez et al. 2012).
In conclusion, our results suggest that P2X7-Rs have a
role in the modulation of trigeminal nociceptive process-
ing. Further investigations of the relations of the trigeminal
system and P2X7-R signalling may provide important
details concerning trigeminal nociceptive processing and
the pathomechanism of headaches.
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Abstract: Probenecid has been widely used in the treatment of gout, but evidence suggests that it may 
also have anti-nociceptive effects in different inflammatory and pain conditions. We examined the 
potential modulatory effects of probenecid on behavioural and morphological markers in the orofacial 
formalin test of the rat. 
One hour after pre-treatment with vehicle or probenecid (1 mmol/kg body weight) intraperitoneally, 
50µl 1.5% formalin solution or physiological saline was injected subcutaneously into the right whisker 
pad of rats. The rubbing activity directed to the injected whisker pad was then measured for a period of 
45 minutes. Four hours after formalin injection, the caudal part of spinal trigeminal nucleus was 
removed and subjected to c-Fos and neuronal nitric oxide synthase (nNOS) immunohistochemistry and 
to interleukin-1β and NAD(P)H:quinone oxidoreductase 1 (NQO1) Western blot. 
There was a significant decrease in formalin-induced biphasic behavioural response and c-Fos and nNOS 
immunoreactivity in the rats that were pre-treated with probenecid. However there were no alterations in expression of 
interleukin-1β or NQO1 after formalin administration. 
Our results suggest that probenecid has an anti-nociceptive effect in the trigeminal inflammatory pain model. This effect 
may be through influencing the release of prostaglandin E2 or desensitizing the transient receptor potential channel 
subtype A member 1 or the transient receptor potential channel subtype V member 2 or the effect may be through 
modulating kynurenic acid levels in the central nervous system. Thus, probenecid might be a potential candidate for the 
treatment of trigeminal activation related pain conditions. 
Keywords: Caudal part of spinal trigeminal nucleus, c-Fos, interleukin-1β, NAD(P)H:quinone oxidoreductase 1, neuronal 
nitric oxide synthase, orofacial formalin test, probenecid. 
INTRODUCTION 
 Probenecid (PROB, p-(di-n-propylsulfamyl)benzoic acid) 
has primarily been used to enhance the renal retention of 
penicillin [1] and to treat gout, due to its ability to increase 
the renal excretion of uric acid [2]. Besides its effects on the 
kidney, research data suggest that PROB may have anti-
inflammatory and anti-nociceptive properties as well. PROB 
blocks the multidrug resistance-associated protein 4 (MRP4), 
an organic anion transporter [3], which is crucial in the 
release of key inflammatory mediators such as prostaglandin  
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E1 and prostaglandin E2 (PGE2) [4]. In addition, PROB 
inhibits the pannexin-1 channel [5], which may be relevant 
in neuronal inflammatory processes [6]. On the other hand, 
PROB is an agonist of the transient receptor potential 
channel subtype A member 1 (TRPA1) [7] and the transient 
receptor potential channel subtype V member 2 (TRPV2) 
[8], which play an important role in pain sensation [9, 10]. It 
is also well known, that an agonist-mediated desensitization 
of these TRPA1 and TRPV2 can be induced [7, 11], leading 
to analgesia. These results strongly suggest that PROB might 
be effective in mitigating inflammation and nociception. In 
contrast, Bang and co-workers raise the possibility that 
PROB can elicit the pain induced by inflammation through 
its agonism on TRPV2 [8]. 
 Fundamental research and pharmacological studies 
investigating the trigeminal inflammation and nociception 
often use the orofacial formalin test, a reliable model for 
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studying somatic pain causing the activation and 
sensitization of trigeminal system [12], which is crucial in 
the pathomechanism of headaches such as migraine [13] - 
one of the most common neurological disorders [14]. 
Formalin solution administered subcutaneously into the 
upper lip gives rise to a tissue injury, nociception and 
inflammation [15], activating the primary nociceptors, 
enhancing the immunoreactivity of c-Fos, a marker of 
neuronal activation [16] in the caudal part of spinal 
trigeminal nucleus (TNC) [17] and resulting in an increase in 
neuronal nitric oxide synthase (nNOS), which is a suggested 
marker of central sensitization [18]. The induction of 
formalin causes a biphasic nociceptive behavioural response 
consisting of rubbing acitivity during an early and short-
lasting (3-4 min) first phase of rubbing is followed by a 
tonic prolonged (20-22 min) second phase, the phases being 
separated by a 9-10 min quiescent period [19]. The first 
phase is thought to be due to the direct chemical stimulation 
of the nociceptors by the formalin solution, while the second 
phase is a manifestation of the processes induced in the 
spinal cord during the first phase, together with peripheral 
inflammation [20]. The inflammatory mediators such as 
PGE2 and interleukin-1β (IL-1 β) and the oxidative stress 
may have important role in the formation of changes induced 
by subcutaneous (s.c.) formalin injection [21-23]. 
 Based on previous experimental results, it has been 
proposed that PROB, through its different receptorial 
actions, may have anti-nociceptive effect that can be seen in 
the orofacial formalin test. Thus the aim of the current study 
was to investigate whether PROB exerts a modulatory effect 
in this tonic trigeminal pain model through the examination 
of behavioural and morphological markers. 
MATERIALS AND METHODS 
Animals 
 The procedures used in this study followed the guidelines 
of the eighth edition of the Guide for the Care and Use of 
Laboratory Animals and the Use of Animals in Research of 
the International Association for the Study of Pain and the 
directive of the European Economic Community 
(86/609/ECC). They were approved by the Committee of 
Animal Research at the University of Szeged (I-74-12/2012) 
and the Scientific Ethics Committee for Animal Research of 
the Protection of Animals Advisory Board 
(XXIV./352/2012.). Sixty adult male Sprague-Dawley rats 
weighing 200-250 g were used. The animals were raised and 
housed under standard laboratory conditions (in an air-
conditioned, humidity-controlled and ventilated room), with 
drinking water and regular rat chow available ad libitum on a 
12h-12h dark-light cycle. Each rat was used only once. 
Drug Administration 
 The rats were divided into two groups (n=30 per group). 
The animals in the Placebo group received only 
intraperitoneal vehicle solution (physiological saline, 1.5 ml) 
as pre-treatment. In the PROB group, the rats were pretreated 
with an intraperitoneal injection of PROB (Sigma-Aldrich; 1 
mmol/kg body weight, diluted to 1.5 ml, pH 7.4). Both 
groups of animals were divided further into two subgroups 
(n=15): 1 hour after the PROB or vehicle pre-treatment, half 
of the animals received a s.c. injection of 50 µl 1.5% 
formalin solution (0.55% formaldehyde, Sigma-Aldrich) 
diluted in physiological saline, administered via a 26-gauge 
needle into the right whisker pad (Placebo-Form and PROB-
Form), while the other half of the rats were injected with s.c. 
50 µl physiological saline without formalin (Placebo-Phys 
and PROB-Phys). 
Behavioural Test 
 The testing procedures were performed during the light 
phase (between 8 a.m. and 2 p.m.) in a quiet room. The test 
box was a 30 x 30 x 30 cm glass terrarium with mirrored 
walls. For the off-line analysis of rubbing activity directed to 
the whisker pad, the behaviour of the individually tested rats 
was recorded with a video camera (Logitech HD Webcam 
C615) situated 1 m above the terrarium. One hour after pre-
treatment with vehicle (n=20) or PROB (n=20) and after a 
10-min habituation in the test box, the whisker pads of the 
rats were injected with s.c. formalin (n=10 per subgroup) or 
physiological saline (n=10 per subgroup) and the animals 
were replaced immediately back in the chamber for 45 min. 
The rats did not receive any food or water during the 
observation period. The test box was cleaned and 
decontaminated after each animal. An observer blind to the 
experimental procedures analysed the recorded videos. The 
45-min recording period was divided into 15x3-min blocks 
and the total time (number of seconds) spent on rubbing the 
injected area with the ipsilateral fore- or hindpaw was 
measured in each block and defined as the nociceptive score 
for that block. Earlier literature findings led us to use the 
grooming activity as control, measured in animals that 
received s.c. physiological saline [15]. 
c-Fos and nNOS Immunohistochemistry 
 Four hours after the formalin or physiological saline 
injection, the rats (n=5-9 per subgroup) were perfused 
transcardially with 100 ml phosphate-buffered saline (PBS), 
followed by 500 ml 4% paraformaldehyde (Merck) in 
phosphate buffer under deep chloral hydrate (0.4 g/kg body 
weight, Sigma-Aldrich) anaesthesia. The medullary segment 
containing the TNC between +1 and -5 mm from the obex 
was removed, postfixed overnight for immunohistochemistry 
in the same fixative and cryoprotected (10% sucrose for 2 h, 
20% sucrose until the blocks sank, and 30% sucrose 
overnight). Before sectioning, each segment was marked 
with a small incision on the ventral and left (contralateral) 
side of the tissue block, allowing side discrimination during 
the quantification process. 30-µm transverse cryostat 
sections were cut through the rostrocaudal axis from the 
beginning of the TNC and were serially collected in wells 
containing cold PBS. Each well contained every tenth 
section at 0.3-mm intervals along the rostrocaudal axis (15 
levels/sections). The free-floating sections were rinsed in 
PBS and immersed in 0.3% H2O2 (Scharlau Chemie) in PBS 
for 30 min to suppress endogenous peroxidase activity. After 
several rinses in PBS containing 1% Triton X-100 (PBST; 
VWR International), sections were incubated at room 
temperature overnight in PBST containing rabbit anti-rat c-
Fos polyclonal antibody (Santa Cruz Biotechnology, sc-52) 
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at a dilution of 1:2000 or at 4°C for two nights in PBST 
containing rabbit anti-rat nNOS polyclonal antibody 
(EuroProxima, B220-1) at a dilution of 1:5,000. The 
immunohistochemical reaction was visualized by using 
Vectastain Elite avidin-biotin kits (Vector Laboratories, 
PK6101). Briefly, the sections were incubated at room 
temperature for 2 hours in PBST containing goat anti-rabbit 
biotinylated secondary antibody. After several rinses in 
PBST, and incubation at room temperature for 2 hours in 
PBST containing avidin and biotinylated horseradish 
peroxidase, the sections were stained with 3,3’-
diaminobenzidine (Sigma-Aldrich) intensified with nickel 
ammonium sulphate (Scharlau Chemie). The specificity of 
the immune reactions was checked by omitting the primary 
antiserum. 
 The counting of immunoreactive (IR) cells in the TNC 
was performed by an observer blind to the experimental 
procedures under the 10x objective of a Nikon Optiphot-2 
light microscope in every tenth transverse section in each 
animal. Before the counting, the location of each section 
along the rostrocaudal axis and the location of the TNC on 
each medullary section were determined by means of The 
Rat Brain in Stereotaxic Coordinates Atlas [24]. The c-Fos 
neurones with obvious specific nuclear staining and the 
nNOS-IR neurones with cytoplasmic and dendritic staining 
and a nucleus were taken into consideration and were 
counted in the TNC both ipsilaterally and contralaterally to 
the formalin or physiological saline injection. 
IL-1β and NAD(P)H:Quinone Oxidoreductase 1 (NQO1) 
Western Blot 
 Four hours after the formalin or physiological saline 
injection, the rats (n=5 per subgroup) were deeply 
anaesthetized with chloral hydrate as described above, 
perfused transcardially with 100 ml ice cold PBS and the 
ipsi- and contralateral side of the TNC between 0 and -4 mm 
from the obex was removed. Until measurements, the 
samples were stored at −80°C. The TNC segments were 
sonicated in ice cold lysis buffer containing 50 mM Tris-
HCl, 150 mM NaCl, 0.1% igepal, 0.1% cholic acid, 2 µg/ml 
leupeptin, 2 mM phenylmethylsulphonyl fluoride (PMSF), 1 
µg/ml pepstatin, 2 mM EDTA and 0.1% sodium dodecyl 
sulphate (SDS) (all chemicals were from Sigma-Aldrich). 
The lysates were cleared from cellular debris by 
centrifugation at 12,000 RPM for 10 min at 4°C and 
supernatants were aliquoted and stored at -20°C. Protein 
concentration was measured according to BCA protein assay 
method with BCA Protein Assay Kit (Novagen) using 
bovine serum albumin as a standard. Samples were cooled 
on ice during the whole procedure. Prior to loading into the 
gels, each sample was mixed with sample buffer, and 
denaturated by boiling for 3 min. Equal amounts of protein 
samples (20 µg/lane) were separated by standard SDS 
polyacrylamide gel electrophoresis (SDS-PAGE) on 12% 
Tris-Glycine gel and electrotransferred onto Amersham 
Hybond-ECL nitrocellulose membrane (0.45 µm pore size, 
GE Healthcare). The Page Ruler Prestained Protein Ladder 
(Fermentas, 10-170 kDa) was used to determine approximate 
molecular weights. Following the transfer, membranes were 
blocked for one hour at room temperature in Tris-buffered 
saline containing Tween 20 (TBST, MP Biomedicals) and 
5% non fat dry milk powder and then incubated in TBST 
containing 1% non fat dry milk and (i) rabbit anti-rat IL-1β 
(H-153) polyclonal antibody (Santa Cruz Biotechnology, sc-
7884, dilution: 1:200, incubation: overnight at 4°C) or (ii) 
rabbit anti-rat NQO1 (H-90) polyclonal antibody (Santa 
Cruz Biotechnology, sc-25591, dilution: 1:200, incubation: 
overnight at 4°C) or (iii) mouse anti-rat β-actin monoclonal 
antibody (Calbiochem, CP01, dilution: 1:100,000, 
incubation: overnight at 4°C). Next day after several rinses 
in TBST, membranes were incubated in TBST containing 
1% non fat dry milk and horseradish peroxidase-conjugated 
anti-rabbit or anti-mouse secondary antibody (Santa Cruz 
Biotechnology; sc-2030 and sc-2031) for 2 hours at room 
temperature. Protein bands were visualized after incubation 
of membranes with the SuperSignal West Pico 
Chemiluminescent Substrate (Pierce) using Carestream 
Kodak BioMax Light film (Kodak). 
 For densitometric analyses, films were scanned and 
quantified using Java ImageJ 1.47v analysis software 
(National Institutes of Health). The β-actin was used as 
sample loading control and normalization protein as well. 
The results from each animal were further normalized to its 
own contralateral side. 
Statistical Analysis 
 In the behavioural study, comparisons were made of the 
rubbing activity in each block of 3-min in each of the 
subgroups (Placebo-Form, Placebo-Phys, PROB-Form and 
PROB-Phys) by using two-way repeated measures ANOVA. 
Subgroups were used as the between-subject factor and 15 
blocks of 3-min as the within-subject factor for the analysis. 
When Mauchly’s test of sphericity proved significant, the 
Greenhouse-Geisser correction was performed. Pairwise 
comparisons of subgroup means were based on the estimated 
marginal means with Sidak adjustment for multiple 
comparisons. 
 To compare statistical differences between subgroups in 
the first and second phases, the two phases were determined 
on the basis of significant results detected during two-way 
repeated measures ANOVA described above. The first phase 
was found to be the first of the 15 blocks, while the second 
phase was the sum of the fifth to the eleventh blocks. To 
determine significant differences between subgroups in the 
first or second phase, we used one-way ANOVA followed 
by the Tamhane post hoc test. 
 In terms of the immunoreactivity, the numbers of IR 
neurones in the various subgroups (Placebo-Form, Placebo-
Phys, PROB-Form and PROB-Phys) were compared at each 
level of 0.3-mm (15 levels) along the rostrocaudal axis by 
using two-way repeated measures ANOVA. Since there was 
no significant difference in the number of c-Fos- and nNOS-
IR neurones between the contralateral sides in the subgroups 
injected with s.c. formalin and the contra- and ipsilateral 
sides in the subgroups injected with s.c. physiological saline 
(data not shown), in the course of the statistical analysis the 
data obtained from the contralateral sides of the subgroups 
injected with s.c. formalin were used as controls. The contra- 
and ipsilateral sides of the formalin-injected subgroups were 
used as the between-subject factor, and the 15 levels along 
the rostrocaudal axis as the within-subject factor for the 
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analysis. When Mauchly’s test of sphericity proved 
significant, the Greenhouse-Geisser correction was 
performed. Pairwise comparisons of subgroup means were 
based on the estimated marginal means with Sidak 
adjustment for multiple comparisons. 
 Statistical analysis of the Western blot data was carried 
out using one-way ANOVA followed by the Sidak post hoc 
test. Since there was no significant difference in band 
densities between the contralateral sides in the subgroups 
injected with s.c. formalin and the contra- and ipsilateral 
sides in the subgroups injected with s.c. physiological saline 
(data not shown), in the course of the statistical analysis the 
data obtained from the contralateral sides of the subgroups 
injected with formalin were used as controls. 
 All tests were two-sided, and probability levels p<0.05 
were considered to be statistically significant. Group values 
are reported as means ± S.E.M. 
 Statistical analysis of measurements was carried out with 
IBM SPSS Statistics, version 20 (IBM Corporation) 
software. 
RESULTS 
Nociceptive Response 
 The behavioural pattern observed in the rats is in 
accordance with previous findings [12, 15, 19]. After the 
formalin injection, the rats immediately withdrew their 
heads, often accompanied by vocalization. Following their 
return to the observation box, the rats started to rub their 
whisker pad continuously and intensely with the ipsilateral 
forepaw accompanied often by the contralateral forepaw, and 
occasionally scraped the perinasal area with the ipsilateral 
hindpaw after a period of ~20 sec. This period, referred to as 
the first phase, lasted ~3-4 min, and was followed by a 
quiescent period of 9-10 min, separating the first phase from 
the second phase. The second phase was characterized by 
less intense, but continuous rubbing of the face, 
predominantly with the ipsilateral forepaw consorted often 
by the contralateral forepaw as well. This tonic phase lasted 
~20-22 min. In the PROB-Form subgroup, the behavioural 
pattern in both phases was clearly less pronounced than that 
in the Placebo-Form subgroup, and such behaviour was not 
witnessed at all in the Placebo-Phys and PROB-Phys 
subgroups, where the animals displayed very little 
rubbing/grooming activity. 
 The comparison of the 3-min blocks revealed significant 
differences in rubbing activity between the Placebo-Form 
and Placebo-Phys subgroups in the first (***p < 0.001) and 
fifth to eleventh (**p < 0.01; ***p < 0.001) blocks (Fig. 1). 
The PROB pre-treatment significantly decreased the 
formalin-induced nociceptive behaviour in each block 
(# #p < 0.01; # # #p < 0.001; Fig. 1). However, it should be 
noted that PROB did not attenuate the effect of formalin 
completely in the first block, where the time spent on 
rubbing was still significantly higher than that in the 
Placebo-Phys subgroup (*p < 0.05; Fig. 1). There was no 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Diagram showing the time (number of seconds) spent rubbing the injected area with the ipsilateral fore- or hindpaw in each block of 
3 min in all 4 subgroups. In the Placebo-Form subgroup (black diamonds), the two phases of formalin action are clearly distinguishable. The 
rubbing activity in the first (***p < 0.001) and in the fifth to eleventh (**p < 0.01; ***p < 0.001) blocks was significantly higher in the 
Placebo-Form subgroup (black diamonds) than in the Placebo-Phys subgroup (dark-grey squares). The PROB pre-treatment significantly 
reduced the formalin-induced nociceptive behaviour in each of the above-mentioned blocks (# #p < 0.01; # # #p < 0.001) in the PROB-Form 
subgroup (black triangles) relative to the Placebo-Form subgroup. There was no significant difference between the findings on the Placebo-
Phys and PROB-Phys animals in any block. 
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significant difference between the Placebo-Phys and PROB-
Phys animals in any block, nor was between the PROB-Form 
and PROB-Phys subgroups in any other block apart from the 
first (Fig. 1). 
 The face rubbing activity in the Placebo-Form subgroup 
was significantly higher during both the first (***p < 0.001) 
and the second phase (***p < 0.001) than that in the 
Placebo-Phys subgroup (Fig. 2). PROB significantly 
decreased the nociceptive behaviour in both phases 
(**p < 0.01; ***p < 0.001; Fig. 2), however this effect was 
not complete in the first phase (*p < 0.05; Fig. 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Diagrams showing the rubbing activity in the first (A) and 
the second (B) phase in all 4 subgroups. In the Placebo group, the 
subcutaneous formalin injection (Placebo-Form) induced a 
significant increase in rubbing activity in both the first and the 
second phase (***p < 0.001) as compared with that in the saline-
treated animals (Placebo-Phys). In both phases, pre-treatment with 
PROB had a significant effect on mitigating the formalin-induced 
increase in the time spent in rubbing (**p < 0.01; ***p < 0.001) as 
compared with the Placebo-Form subgroup. 
c-Fos in the TNC 
 Microscopic examination of the immunostained 
transverse sections of the TNC revealed c-Fos 
immunoreactivity in the nuclei of the neurones. In the 
Placebo-Form subgroup, unilateral s.c. formalin injection 
produced an increase in the number of c-Fos-IR neurones in 
the dorsal, superficial area of the transverse sections of the  
 
ipsilateral TNC as compared with the non-treated 
contralateral side (Fig. 3A). This increase was significant at 
different levels along the rostrocaudal axis (between -0.3 and 
-3.3 mm), in accordance with the somatotopic representation 
(**p < 0.01; ***p < 0.001; Fig. 3C). 
 In the PROB-Form subgroup, the number of c-Fos-IR 
neurones at the different levels along the rostrocaudal axis 
also increased in the ipsilateral TNC. This effect was similar, 
but less pronounced than that in the Placebo-Form subgroup 
(Fig. 3B), i.e. PROB significantly decreased the formalin-
related activation of the second order trigeminal neurones at 
several levels of the TNC (between -0.3 and -2.4 mm; 
#p < 0.05; # #p < 0.01; # # #p < 0.001; Fig. 3C). On the 
contralateral sides of the TNCs, there were no significant 
differences either between the subgroups or between the 
different levels along the rostrocaudal axis (Fig. 3). 
nNOS in the TNC 
 On the immunostained transverse sections, the nNOS-IR 
neurones showed cytoplasmic and dendritic staining. The 
unilateral s.c. formalin injection gave rise to an increase in 
the number of nNOS-IR neurones in the dorsal, superficial 
area of the ipsilateral TNC compared to the non-treated 
contralateral side in the Placebo-Form subgroup (Fig. 4A). 
Along the rostrocaudal axis, significant increase can be 
observed at different levels (between -2.1 and -2.7 and 
between -3.3 and -3.9 mm; *p < 0.05; **p < 0.01; Fig. 4C). 
In the PROB-Form subgroup, there was no difference in the 
number of nNOS-IR neurones between ipsilateral and 
contralateral TNC (Fig. 4B), i.e. PROB significantly 
decreased the number of the second order trigeminal 
neurones expressing nNOS at several levels of the TNC 
(between -2.1 and -2.7 and between -3.3 and -3.9 mm; 
#p < 0.05; # #p < 0.01; Fig. 4C) at the injected side. On the 
contralateral sides of the TNCs, there were no significant 
differences either between the subgroups or between the 
different levels along the rostrocaudal axis (Fig. 4). 
IL-1β and NQO1 in the TNC 
 The Western blot analysis of the TNC segments did not 
show significant difference between the contra- and 
ipsilateral sides for any of the subgroups either in the case of 
IL-1β or in the case of NQO1 (data not shown), which means 
that IL-1β or NQO1 expression did not change four hours 
after the unilateral s.c. formalin injection and PROB pre-
treatment did not have any modulatory effect on the 
expression of IL-1β or of NQO1. 
DISCUSSION 
 This is the first study showing that PROB produced a 
pronounced anti-nociceptive behavioural effect in the 
orofacial formalin test especially in the second phase. PROB 
exhibited no effect on the baseline activity of the control 
animals, which received a s.c. saline injection in the whisker 
pad. In addition to the modulation of the nociceptive 
behaviour, PROB also mitigated the formalin induced c-Fos 
and nNOS expression in the TNC - considered markers of 
activation and sensitization of these neurones [16, 18]. 
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 This anti-nociceptive effect of PROB along with its 
inhibitory effect on the trigeminal activation and 
sensitization can be the result of various mechanisms: 
 PROB inhibits MRP4, an organic anion transporter [3], 
which releases key inflammatory mediators such as 
prostaglandin E1 and PGE2 from cells in a time- and ATP-
dependent manner [4], and these mediators contribute to 
inflammation and hyperalgesia [25, 26]. PGE2 released from 
cultured rat trigeminal ganglion nerve cells [27] can sensitize 
transient receptor potential channel subtype V member 1 
(TRPV1) [28] (a key factor in the development of 
sensitization during nociception [29]). Moreover, PGE2 can 
induce calcitonin gene-related peptide (CGRP) release (a 
general event after the activation of first order trigeminal 
neurones [30]) from cultured trigeminal ganglion cells [31]. 
PGE2 can also act on the trigeminal system at the level of 
the central nervous system by enhancing the capsaicin-
induced CGRP release in slice preparations of the TNC [32]. 
The expression of cyclooxygenase-2 (an inducible enzyme 
of prostaglandin synthesis [33]) has also been detected in the 
neurones and glial cells in the trigeminal ganglion [31] and 
in the neurones of the TNC [34]. In addition, prostaglandin 
receptors play a relevant role in trigeminal nociception and 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). (A) c-Fos-immunoreactive (IR) neurones (black arrow) in the superficial laminae of a transverse section of medulla containing the 
caudal part of the spinal trigeminal nucleus (TNC) in the Placebo-Form subgroup. Subcutaneous formalin injection resulted in a higher 
number of c-Fos-IR neurones on the ipsilateral side than on the contralateral side. Scale bar: 500 µm. (B) c-Fos-IR neurones on the formalin-
treated ipsilateral sides of sections in the TNC in the two subgroups. The formalin-induced increase in IR cells was more prominent on the 
ipsilateral side in the Placebo-Form subgroup (B/a) than in the probenecid (PROB) (B/b)-pretreated animals. Scale bar: 200 µm. (C) Diagram 
showing the mean number of c-Fos-IR cells in the superficial laminae of the TNC at different levels along the rostrocaudal axis (mean ± 
S.E.M, n=9 per subgroup). In the Placebo-Form subgroup, formalin produced a significantly higher number of c-Fos-IR neurones on the 
formalin-treated side of the TNC as compared with the contralateral side at different levels along the rostrocaudal axis (between -0.3 and -3.3 
mm), in accordance with the somatotopic representation (**p < 0.01; ***p < 0.001). PROB pre-treatment significantly decreased the effect 
of formalin between -0.3 and -2.4 mm (#p < 0.05; # #p < 0.01; # # #p < 0.001). 
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in the pathomechanism of trigeminal activation [35, 36]. 
They are present in the trigeminal ganglion [37], co-
expressed with TRPV1, with a functional interaction 
between them in the trigeminal system [38, 39], and are 
involved in mediating CGRP release from cultured rat 
trigeminal neurones [40]. Quantitative autoradiography has 
revealed that TNC has a moderate density of PGE2 binding 
sites [41] as well, and the mRNA of all prostaglandin 
receptors are also present there [37]. Accordingly, a possible 
mechanism of action of PROB is the inhibition of the release 
of PGE2, a key player in trigeminal nociception and an 
important molecule in migraine genesis [42] through the 
blockade of MRP4. 
 PROB also inhibits the pannexin-1 channel [5], which 
may be relevant in inflammation [6] and hence in pain 
processing. The pannexin-1 channels are mainly expressed in 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). (A) Immunostained transverse sections of medulla containing the caudal part of the spinal trigeminal nucleus (TNC) from the 
Placebo-Form and probenecid (PROB)-Form subgroup. Black arrow shows the neuronal nitric-oxide synthase (nNOS)-immunoreactive (IR) 
neurones in the superficial area of the TNC. On the ipsilateral side (A/b), more nNOS-IR neurones can be observed than on the contralateral 
side (A/a) in the Placebo-Form subgroup. After formalin injection, there is a lower number of nNOS-IR neurones on the ipsilateral side in the 
probenecid (PROB)-Form subgroup (A/d) than in the Placebo-Form subgroup (A/b). In these two subgroups, difference between the 
contralateral sides cannot be observed. Scale bar: 200 µm. (B) Diagram showing the mean number of nNOS-IR cells in the superficial area of 
the TNC at different levels along the rostrocaudal axis (mean ± S.E.M, n=5 per subgroup). Formalin produced a significant increase in 
number of nNOS-IR neurones on the formalin-treated side of the TNC in the Placebo-Form subgroup as compared with the contralateral side 
at different levels along the rostrocaudal axis (between -2.1 and -2.7 and between -3.3 and -3.9 mm; *p < 0.05; **p < 0.01). The effect of 
formalin was significantly decreased by pre-treatment with PROB between -2.1 and -2.7 and between -3.3 and -3.9 mm (#p < 0.05; 
# #p < 0.01). There was no significant difference between the contralateral sides. 
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the spinal cord [43]; moreover, they are present in the 
postsynaptic neurones [44] and are crucial in caspase-1 
activation, which leads to the production and release of 
interleukin-1beta (IL-1β) in neurones, astrocytes [6] and 
macrophages [45]. The release of IL-1β from trigeminal 
ganglion satellite cells may contribute to the mechanisms 
underlying trigeminal inflammatory hyperalgesia [46]. Up-
regulation of astrocytic IL-1β in the TNC can lead to central 
sensitization via its receptors present on trigeminal neurones 
in the same area [47, 48]. The interleukin-1 receptor 
antagonists were effective in modulation of changes caused 
by noxious stimulation [26, 49]. Consequently, these results 
clearly indicate that IL-1β plays a role in trigeminal 
activation. However the results of our Western blot 
measurement showed that there were not changes in the 
expression of IL-1β at the level of TNC four hours after s.c. 
formalin administration and therefore it is not possible that 
PROB exerts such effect on this level, but one can not 
exclude the possibility that PROB affects IL-1β in the 
periphery, at the inflammation site or in the trigeminal 
ganglion. 
 It is important to note that some data suggest that PROB 
is able to activate some of the transient receptor potential 
channels, including TRPV2 and TRPA1 [7, 8] which play an 
important role in pain perception [9, 10] and are present in 
the trigeminal system [50-52]. However, the agonist-
mediated desensitization of these receptors is also known [7, 
11], which can cause an anti-nociceptive effect [53, 54]. 
PROB can desensitize the TRPA1 [7] and may act similarly 
on TRPV2 as well, which might account of its anti-
nociceptive properties in the present experiments. 
 It is a well-known fact that PROB can increase the 
concentration of kynurenic acid - an endogenous tryptophan 
metabolite [55] - in the central nervous system [56]. This 
phenomenon can be caused by inhibition of organic anion 
transporters by PROB [57, 58], which are involved in the 
transport of kynurenic acid taking place from brain through 
the blood-brain barrier [59] or by increasing of concentration 
of tryptophan in the central nervous system [60]. 
Experimental data suggest that kynurenic acid can affect 
nociception [61-64] and elevation in its concentration in the 
brain can inhibit the trigeminal activation [65, 66], probably 
due to an antagonistic effect on ionotropic glutamate and α7-
nicotinic acetylcholine receptors [67-69] or due an agonistic 
action on G-protein-coupled receptor-35 [70], which 
receptors play important role in pain processing and 
trigeminal activation [71]. 
 Several lines of evidence confirm the role of oxidative 
stress in the induction of tissue damage e.g. neuronal 
activation caused by inflammation in orofacial formalin test 
[23, 72]. However, in the present study, we could not support 
this hypothesis, since the NQO1 expression, a marker of 
oxidative stress [73, 74], remained unchanged four hours 
after s.c. formalin injection. 
CONCLUSION 
 The results of our study provide evidence that pre-
treatment with PROB can have anti-nociceptive effects and 
can modulate the changes induced by trigeminal 
inflammation in both behavioural and morphological 
markers in the rat orofacial formalin test. PROB may exert 
this effect through inhibition of the inflammatory processes 
which could be through blocking the MRP4, which induces 
the release of key inflammatory mediators such as PGE2 or 
through desensitization of TRPA1 and TRPV2 or by 
enhancing concentration of kynurenic acid in the brain. 
These properties and the relatively good side effect profile 
can make PROB a possible pharmacological candidate in the 
treatment of trigeminal activation related pain. 
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Abstract Migraine is a common neurological condition,
causing high disability, but the pathomechanism of the
disease is not yet fully understood. Activation of the
trigeminovascular system could play a crucial role in
the manifestation of the symptoms, but initial step of this
activation remains unknown. Functional imaging studies
have revealed that certain brainstem areas, referred to as
migraine generators, are activated during a migraine attack,
including the dorsal raphe, the periaqueductal gray, the
locus coeruleus, and the nucleus raphe magnus. However,
the studies performed to date have not demonstrated
whether this activation is a trigger or a consequence of the
migraine attack. With the aim of evaluating the functional
relationship between activation of the trigeminal system
and migraine generators, we examined the changes in c-Fos
immunoreactivity in the above-mentioned nuclei after
stimulation of the trigeminal ganglion, an animal model for
trigeminovascular activation. The stimulation led to sig-
niﬁcant increases in the number of c-Fos immunoreactive
cells in the nucleus raphe magnus and in the caudal part of
the spinal trigeminal nucleus, 2 and 4 h after the stimula-
tion. Activation of the trigeminal system failed to exhibit
uniform activation of the brain stem nuclei related to
migraine. Our results suggest that the activation of the
trigeminal system in the rat by electrical stimulation of
the trigeminal ganglion leads to the activation of the
descending pain modulatory system, but not to the acti-
vation of ‘‘migraine generator’’ nuclei. Therefore, the
activity pattern seen in functional studies may reﬂect a
unique feature, exclusively present in migraine.
Keywords Migraine generators  C-Fos  Electrical
stimulation of the trigeminal ganglion  Rat
Introduction
Migraine is a neurological disorder, with an unrevealed
pathomechanism. Over the years, many theories have
emerged as the cause of the disease; vascular, neurogenic,
and genetic processes have been proposed, but none of
these could provide a reliable explanation of all the events
related to this disorder [1].
During a migraine attack, the trigeminovascular system
is activated, neuropeptides and inﬂammatory mediators are
released, leading to neurogenic inﬂammation with vasodi-
lation and plasma extravasation which can activate the
trigeminal nociceptors and cause pain [2].
The activation and sensitization of the trigeminal system
play a crucial role in migraine pathomechanism. These
activation processes affect the caudal part of the spinal
trigeminal nucleus (TNC); therefore, numerous studies
have examined the activation pattern of this nucleus in
different animal models [3], but the very ﬁrst step, which
leads to these phenomena, remains unexplained.
Functional imaging studies have revealed activation of
the dorsolateral pons and the dorsal midbrain during a
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migraine attack, this activation persisting even after suc-
cessful treatment with antimigraine agents [4], which
suggests that this brainstem activation is not related to the
perception of pain itself. The experimental results tend to
support this view since cranial pain elicited by capsaicin
did not give rise to brainstem activation [5]. The data
suggest that the dorsal midbrain and dorsolateral pons,
including the periaqueductal gray (PAG), the dorsal raphe
(DR), the nucleus raphe magnus (NRM), and the locus
coeruleus (LC), are involved in migraine headache. Since
most of the reported functional imaging studies were car-
ried out in the course of a migraine attack, it has not been
ascertained whether the activation of this region is a cause
or an effect of the attack.
The NRM comprises part of the descending pain mod-
ulatory system receiving strong input from the cerebral
cortex [6]. Stimulation of the NRM can modify the noci-
ceptive input at the level of the spinal trigeminal nucleus
[7], and the activity of the NRM can be modulated by
agents effective in migraine therapy, suggesting a crucial
role in the pathomechanism of migraine [8].
The DR, one of the largest serotonergic nuclei in the
central nervous system, plays an important part in noci-
ceptive processing and antinociception [9]. This nucleus is
activated during trigeminal nociception, thus it is possibly
involved in the pathomechanism of migraine [10].
The LC is the main source of norepinephrine in the
central nervous system, sending projections both to higher
brain structures and to the spinal cord dorsal horn [11]. The
LC has been suggested to possess a function parallel to
that of NRM in pain control [12]. It has strong projection to
the TNC [13], with a possible regulatory role, and sends
direct projections to intracranial and extracranial vessels,
suggesting an involvement in the vascular events of
migraine [14].
Electrical stimulation of the PAG in humans resulted in
analgesia [15], but chronic implants, mainly situated in
the ventrolateral PAG (VLPAG), caused migraine-like
symptoms in some cases [16], implying a role in pain
modulation and migraine generation. Experimental and
clinical ﬁndings have revealed that the PAG is a member
of the descending pain modulatory system, which receives
input from the spinal cord dorsal horn and from higher
brain structures [17]. The PAG can be divided into
longitudinal columns, each with different functions, sug-
gesting an integrative role in pain processing, emotional
and autonomic regulation [17]. The VLPAG is activated
by trigeminal pain in animals [18], indicating that this
area has as an integrative role in trigeminal sensory
modulation.
Electrical stimulation of the trigeminal ganglion causes
structural alterations in calcitonin gene-related peptide
positive sensory nerve terminals [19], furthermore it leads
to the extravasation of albumin from the vessels of the dura
mater [20]. These results indicate that electrical stimulation
of the trigeminal ganglion could induce chemical and
vascular changes similar to those during migraine pain.
It is clear that the above-mentioned nuclei play an
important part during a migraine attack, but it is still
unknown whether their role is active or passive. The aim of
our study was to investigate their pattern of activation and
to evaluate possible functional connections between them
and the trigeminal system in an experimental trigeminal
activation model, electrical stimulation of the trigeminal
ganglion.
Materials and methods
The procedures of this study conformed to the guidelines of
the International Association for the Study of Pain and the
European Communities Council (86/609/ECC). They were
approved by the Ethics Committee of the Faculty of
Medicine, University of Szeged, and by the Committee of
Animal Research at the University of Szeged (I-74-14-16/
2008) and the Scientiﬁc Ethics Committee for Animal
Research of the Protection of Animals Advisory Board
(XI./15.1/02384/001/2007).
Adult male Sprague–Dawley rats (weighing between
280 and 340 g) were used. The animals were raised and
maintained under standard laboratory conditions, with tap
water and regular rat chow available ad libitum, on a
12:12 h dark–light cycle.
Stimulation
Twenty-six rats were divided into two groups. The animals
in the ﬁrst group (n = 13) were deeply anaesthetized with
chloral hydrate (400 mg/kg) and placed in a stereotaxic
instrument (Stoelting Co., Wood Dale, USA). A hole was
drilled with a dental drill 3.2–3.4 mm posterior to and
2.8–3.2 mm laterally from the bregma. A concentric
bipolar electrode (FHC Inc., Bowdoin, USA, CBBRE75)
was lowered to the right trigeminal ganglion, and main-
tained in it for 30 min. After surgery, the animals were kept
under deep anaesthesia, with additional doses of chloral
hydrate, if needed, being given. They were returned back to
their cages and were kept warm.
The animals in the second group (n = 13) underwent a
similar surgical procedure, but were additionally stimulated
for 30 min with square pulses at 10 Hz, 0.5 mA, with a
pulse duration of 5 ms. The applied stimulation frequency
induces depolarization, thus rapid ﬁring of the pseudouni-
polar neurones of the trigeminal ganglion, and the intensity
applied ensures that the area of the stimulation covers the
entire trigeminal ganglion [21].
1598 Neurol Sci (2013) 34:1597–1604
123
The correct placement of the electrode was checked via
the twitching of the jaw when the electrode reached the
ganglion, and was conﬁrmed during the autopsy.
From both the groups, seven animals were perfused
transcardially 2 h after the placement of the electrode, while
six animals were perfused 4 h after the electrode placement,
with 100 mL cold 0.1 M phosphate buffered saline (PBS),
followed by 500 mL 4 % paraformaldehyde in 0.1 M
phosphate buffer. The brains and cervical spinal cord were
removed and postﬁxed overnight in the same ﬁxative.
Immunohistochemistry
After cryoprotection 30 lm thick serial sections were cut
1 mm rostrally and 5 mm caudally from the obex, repre-
senting the TNC. The series were collected into 18 wells,
and the distance between consecutive sections was
540 lm.
Similarly 30 lm thick serial sections were cut from the
brainstem, the series started 1.5 mm rostrally from the
obex and 30 series were cut from each animal. The series
Fig. 1 Representative photos
of the caudal part of the spinal
trigeminal nucleus from a
sham animal (a, c) and from
a stimulated one
(b, d) approximately 0.5 mm
caudal from the obex. In sham
animals, there was no noticeable
difference between the control
and the electrode side regarding
the number of c-Fos IR cells (a).
However, in stimulated animals
a remarkable increase in the
number of c-Fos IR cells could
be observed at the stimulated
side (d) compared to the control
side of the same animal (b) and
also compared to the electrode
side of sham animals (c).
Rectangles on picture a and
b indicate the origin of pictures
c and d, both from the sides of
animals associated with the
electrode. Scale bars indicate
500 lm on a and b, and 100 lm
on c and d
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were collected into 10 wells, the distance between con-
secutive sections therefore being 300 lm.
The free-ﬂoating sections were rinsed in PBS and
immersed in methanol containing 0.3 % H2O2 for 30 min.
After several washes in PBS containing 1 % Triton X-100
(PBS-T), the sections were blocked for 1 h in PBS-T
containing 10 % normal goat serum (NGS). Sections from
the TNC were incubated for one night at room temperature
in PBS-T containing 2 % NGS and 1:2,000 anti c-Fos
primary antibody (Santa Cruz Biotechnology, Santa Cruz,
USA, sc-52), while sections from the brainstem were
incubated for two nights at 4 C in PBS-T containing 2 %
NGS and 1:1,000 anti c-Fos primary antibody (Santa Cruz
Biotechnology, Santa Cruz, USA, sc-52). The immuno-
histochemical reaction was visualized using the
avidin–biotin kit of Vectastain (Vector Laboratories Inc.,
Burlingame, USA, PK-6101) and stained with nickel
ammonium sulfate-intensiﬁed 3,30-diaminobenzidine for
sections of the TNC and 3,30-diaminobenzidine without
intensiﬁcation for sections of the brainstem. The speciﬁcity
of the immune reaction was checked by omitting the pri-
mary antiserum. On brainstem sections toluidine blue
counterstaining was applied to facilitate cell counting.
Cell counting
The c-Fos-immunopositive cells were counted according to
Paxinos and Watson [22] in the TNC, NRM, DR, VLPAG,
lateral periaqueductal gray (LPAG), dorsolateral periaqu-
eductal gray (DLPAG), dorsomedial periaqueductal gray
(DMPAG), and LC separately. Sections were examined
under a Zeiss Axio Imager M2 Upright Microscope (Carl
Zeiss MicroImaging, Go¨ttingen, Germany) supplied with
an AxioCam MRc camera (Carl Zeiss MicroImaging,
Go¨ttingen, Germany). Photographs were taken on 209
magniﬁcation, using the MosaiX program feature of the
AxioVision programme. Cells were counted and area of the
different nuclei was delineated and measured on one series
of sections from the TNC and from the brainstem in
each animal. Cell counting was made by an investigator
blinded to the stimulation procedure, furthermore stimu-
lated and unstimulated sides of the sections were counted
separately.
Statistical analysis
For the different nuclei, cell counts per side and per series
were summed and divided by the corresponding area. In
this way, the cell count per lm2 was calculated for each
side and for each series in each animal.
In case of the TNC counts were averaged by animal and
statistical comparison was made using ANOVA (SPSS
Statistics 17.0 for Windows, Games–Howell post hoc test).
In case of other paired nuclei of the brainstem, the ﬁrst
step was to determine if there is any difference between the
sham and stimulated sides using Student’s t test. There was
no signiﬁcant difference in any of the nuclei; therefore,
data from separate sides were pooled. These data were than
compared using ANOVA (SPSS Statistics 17.0 for Win-
dows, Scheffe post hoc test).
Statistical comparison in the NRM and DR was also
conducted by ANOVA (SPSS Statistics 17.0 for Windows,
Scheffe post hoc test).
Results
The surgical procedure and lowering of the electrode to
the trigeminal ganglion did not cause signiﬁcant increase
in the number of c-Fos immunoreactive (IR) cells on the
ipsilateral side of the TNC neither in the 2 h nor in the
4 h survival group (Figs. 1c, 2). On the contralateral
(control) side, no changes could be observed (Figs. 1a, 2).
After electrical stimulation, a marked increase was
observed on the ipsilateral and a slight increase on the
contralateral side of the TNC at both survival times
(Fig. 1b, d), from which only the changes on the ipsilat-
eral side proved to be signiﬁcant (Fig. 2). There was no
difference in the activation of the TNC between the two
stimulated groups.
It is interesting that we found differences in lateraliza-
tion only in the TNC, in the other nuclei namely the VL, L,
DL, DM PAG, and LC, there was no difference between
the stimulated and unstimulated sides (data not shown).
Fig. 2 Diagram showing the average number of c-Fos IR cells per
lm2 in the caudal part of the spinal trigeminal nucleus (TNC, group
means per side ? SEM). After sham surgery only a slight non-
signiﬁcant increase can be detected, while after electrical stimulation
of the trigeminal ganglion a signiﬁcant increase is present in the TNC
both at 2 and 4 h of survival (*p\ 0.05; **p\ 0.01) compared to
sham stimulated animals. There is no signiﬁcant difference between
the stimulated sides of the two distinct survival times
1600 Neurol Sci (2013) 34:1597–1604
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In the NRM, stimulation produced signiﬁcant (p\ 0.05)
increase in the number of c-Fos IR cells, mainly in
the rostral part of the nucleus at both survival times
(Fig. 3c, e) compared to the animals with sham stimulation
(Fig. 3b, d).
In case of the other nuclei, no statistically signiﬁcant
alteration could be observed between the sham and
stimulated groups, although a tendency of increase in the
DR and LC could be noticed (Fig. 4).
To evaluate if there is any relationship between the TNC
and the NRM regarding the increase in the cell numbers,
linear regression analysis was performed (SPSS Statistics
17.0 for Windows). No correlation was found between the
two nuclei (R2 = 0.252; F = 3.708; p = 0.80).
Fig. 3 Representative photos of
the nucleus raphe magnus from
a stimulated (a, c, e) and a sham
animal (b, d) 2 (a, b, c) and 4 h
(d, e) after stimulation
approximately 4 mm rostral
from the obex. Rectangle in a
indicates the location where c;
b, d and e were taken. Filled
arrowheads indicate c-Fos
positive cells, while unfilled
arrowheads indicate c-Fos
negative cells, counterstained
with toluidine blue. After 2 h of
survival, c-Fos immunoreactive
cells are more numerous in the
stimulated group (c). 4 h after
the stimulation the activation of
the nucleus raphe magnus is still
present (e). Scale bars indicate
1,000 lm on a; and 200 lm on
b, c, d and e
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Discussion
In this study, we ﬁrst demonstrated that electrical stimu-
lation of the trigeminal ganglion, i.e., activation of the
trigeminal system, in the rat does not lead to the uniform
activation of ‘‘migraine generator nuclei’’.
Electrical stimulation of the trigeminal ganglion has a
direct effect on the primary trigeminal sensory neuron
causing alterations in both the peripheral and the central
endings. In the periphery, mediators from the nerve
endings around the meningeal vessels are released, which
results in plasma protein extravasation and eventually
neurogenic inﬂammation [20]. In the central arm, there is a
marked activation of the second-order neurones in the TNC
[23]. Our results are in accordance with these previous
ﬁndings as we found marked increase in the number of
c-Fos IR cells in the ipsilateral TNC both 2 and 4 h after
stimulation. This pronounced increase may arise directly
from the electrical stimulation or is a secondary phenom-
enon originating from the periphery due to the triggered
dural extravasation and inﬂammation [20]. The activation
of second-order neurones is followed by activation of the
third-order thalamic and cortical neurones [24].
We observed a signiﬁcant increase in neuronal activity
in the NRM in the 2 h survival group, which persisted even
4 h after the stimulation, however a tendency of decrease
could be noticed. Direct TNC projections to the NRM are
sparse [25], and the superﬁcial laminae, which are mainly
activated in response to electrical stimulation, display even
fewer connections to the NRM [26]; accordingly activation
of the TNC may not evoke a direct NRM activation. This
hypothesis is further supported by the fact that we did not
ﬁnd any correlation between the increased cell activities in
the two nuclei neither after 2 nor after 4 h, suggesting that
the activation of the NRM may not be a direct consequence
of the activation of the TNC. Although there is no corre-
lation between the activation patterns of these two nuclei,
the increase in their activity is present simultaneously at
both 2 and 4 h after stimulation.
Fig. 4 Diagram showing the average number of c-Fos IR cells per
lm2 in brainstem nuclei (group means ? SEM). The highest cell
number per area ratio was present in the locus coeruleus, which is not
surprising, considering the small extent of this nucleus. Statistically
signiﬁcant alteration between the sham and stimulated group could
only be detected in the nucleus raphe magnus (*p\ 0.05). There is a
signiﬁcant difference (*p\ 0.05) between the two stimulated groups
in case of the locus coeruleus, but no such difference could be
observed in the other nuclei. In the nucleus raphe magnus the
stimulation increased the number of c-Fos IR cells. LC locus
coeruleus, DR dorsal raphe, NRM nucleus raphe magnus, VL PAG
ventrolateral periaqueductal gray, L PAG lateral periaqueductal gray,
DL PAG dorsolateral periaqueductal gray, DM PAG dorsomedial
periaqueductal gray
Fig. 5 Schematic route of activation based on our ﬁndings. Electrical
stimulation activates the secondary trigeminal sensory nuclei in the
TNC, the activation travels to the thalamus and the cortex. Activation
of the NRM is probably secondarily related to the thalamus
1602 Neurol Sci (2013) 34:1597–1604
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After intracisternal administration of capsaicin, there is
an elevation in the number of c-Fos immunoreactive cells
in the NRM [10], suggesting a role in trigeminal noci-
ceptive processing. The NRM is thought to be the main
output of the descending pain modulatory system, provid-
ing dense innervations to the spinal cord dorsal horn. We
assume that activation of the NRM may be a consequence
of activation of the descending pain modulatory system.
This activation could result from the cortical and thalamic
input of the NRM, or it could originate from the PAG [25].
There is no evidence that the TNC projects directly to
the DR [27]. The DR forms part of the pain modulatory
system in both ascending and descending directions [9],
and the DR receives dense afferents from the NRM, but
cortical input can also modulate the activity of this nucleus
[27]. We did not ﬁnd signiﬁcant change in the number of
c-Fos IR cells in the DR after electrical stimulation of the
TG. Our results suggests that the activation of the tri-
geminal system does not cause the activation of the DR,
and thus in the rat, this nucleus may not participate in the
short-term regulation of trigeminal nociceptive processing.
The LC is activated after painful stimuli [10, 28], sug-
gesting an important role in nociceptive processing and
modulation, however, activation due to stressful circum-
stances is also possible [29]. Our results indicate that after
electrical stimulation of the TG, activity of the cells in the
LC does not change, although it is noticeable that the
activity of the LC is already pronounced in the sham group
2 h after the stimulation, suggesting that the stress and the
possible pain caused by the surgical procedure may
obscure the changes caused by the electrical stimulation.
After 4 h of survival, the activity level of the LC is
decreasing both in the sham and stimulated groups, further
supporting our view that the activation of the LC is due to
the invasive procedure.
The available information relating to TNC and LC direct
inputs is controversial, some authors reporting that the
TNC sends only a sparse direct input to the LC [30], and
others describing the existence of neuronal input from
lamina I to the LC. Our results indicate that the TNC may
not have direct input to the LC [31]. It is possible that the
contribution of LC to the descending pain modulatory
system is via the NRM [32]; however, it is a well-known
fact that LC has a descending projection to the spinal cord,
which could modulate nociceptive processing directly.
No change in the number of c-Fos immunoreactive
nuclei were noticed in any region of the PAG. There is a
direct connection between the TNC and the PAG, thus it is
surprising that a strong stimulus like we applied caused no
alteration in this area. Previous studies indicated an
increase in activity of the PAG after nociceptive stimula-
tion [18], although the stimulation parameters and settings
differed from those we applied.
If it is assumed that the changes seen in our experiments
are secondary, the lack of direct projections from the TNC
to most of the above-mentioned nuclei supports this
hypothesis. In this conception, the stimulation activates the
ascending nociceptive routes to the thalamus and to the
cortex, and these structures react to the nociceptive input
by activating the descending modulatory system (Fig. 5).
After trigeminal stimulation, the examined nuclei failed to
exhibit the uniform activation detected during a migraine
attack suggesting that this activation pattern of the
migraine generator nuclei may be exclusively present in
migraine.
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